Stockwinners Market Radar for February 15, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:37 EST DexCom CEO sells $1.25M in common stock - In a regulatory filing, DexCom disclosed that its CEO Kevin Sayer sold 3K shares of common stock on February 14th in a total transaction size of $1.25M.

20:24 EST Cathie Wood's ARK Investment bought 37K shares of 2U today

19:40 EST Roblox reports January revenue $203M-$206M, up 64%-66% y/y - In its Q4 earnings press release, Roblox also reports January DAUs at 54.7M, up 32% from January 2021. Hours engaged were 4.2B, up 26% y/y. Bookings were $220M and $223M, up 2% - 3% y/y.

19:01 EST CMC Materials reports 'favorable' conclusion in patent dispute with DuPont - CMC Materials, Inc. (CCMP) announced the conclusion of United States Presidential review, thereby affirming the company's "favorable" Final Determination in its International Trade Commission case against DuPont de Nemours (DD) and several DuPont subsidiaries. As announced in December, the ITC found DuPont is unlawfully importing, selling, and marketing in the United States certain chemical mechanical planarization slurries and components thereof that infringe a patent owned by CMC that is fundamental to advanced dielectric CMP slurries. In that ruling, the ITC issued an exclusion order and cease and desist orders prohibiting DuPont's importation, marketing, and sale of infringing products and components thereof in the United States, pending a 60-day Presidential review period. Now that the period has expired, United States Customs and Border Protection will stop the importation into the United States of DuPont's infringing Optiplane 2300 and Optiplane 2600 dielectric CMP slurries and components thereof for a period extending to 2035. Under the December Final Determination, a party expecting to "transition away" from the infringing products in the short term must submit to CBP a "documented need" for the products under penalty of criminal sanction.

18:02 EST Moderna to expand footprint in Asia with four additional subsidiaries - Moderna Hong Kong. This expansion comes as the Company continues to scale up the manufacturing and distribution of its COVID-19 vaccine and future mRNA vaccines and therapeutics. The Asia-Pacific region represents an integral part of Moderna's business, with established subsidiaries in Japan, South Korea, and Australia. In 2021, Moderna and the South Korean government announced a collaboration to explore local opportunities for research and manufacturing in South Korea. More recently, the company announced an agreement in principle with the Australian Government to build a state-of-the-art mRNA vaccine manufacturing facility in Victoria, Australia. "2021 was a year of impact for Moderna, and I am proud to see continued growth in 2022 as we expand our presence in Asia. After a decade of pioneering the development of our mRNA platform, we were ready to play a critical role in combating the COVID-19 pandemic globally," said Stephane Bancel, Chief Executive Officer of Moderna. "With the addition of four subsidiaries in Asia, we look forward to new opportunities to leverage our mRNA platform to help solve health challenges, including those with a high burden of disease in the Asia-Pacific region."

17:55 EST American Airlines signs firm order with Embraer for three new E175s - American Airlines (AAL) has signed a firm order with Embraer (ERJ) for three new E175s. The aircraft will be operated by American's wholly owned subsidiary, Envoy Air. With deliveries to be completed this year, Envoy's fleet of E175s will grow to over 100 aircraft by the end of 2022. The contract value is $160.2M at current list prices and will be included in Embraer's 2021 fourth quarter backlog.

17:24 EST Corsair Gaming to replace First Midwest in S&P 600 at open on 2/18

17:21 EST EnLink Midstream sees 2022 net income $230M-$310M

17:18 EST U.S. Steel CFO Breves to leave company in 2022 - U.S. Steel announced that Christine S. Breves, Senior Vice President & Chief Financial Officer, has informed the company of her intention to leave the company in 2022, after nine years of service with the company. Breves will continue to serve as Chief Financial Officer while the company conducts a search for a permanent replacement. To ensure the company gains the full benefit of her extensive financial and supply chain expertise, Breves has agreed to stay on as Executive Vice President - Business Transformation to support the company's Best for All strategy. "Christie's deep knowledge of the industry, leadership and superb insight have contributed greatly to U. S. Steel's transformation into the future of steelmaking," said U. S. Steel President and Chief Executive Officer David B. Burritt. "We have too much important work before us not to take full advantage of her capabilities. That's why I'm so pleased that Christie elected to remain for the full year and our Board of Directors agreed to elevate her to Executive Vice President. I look forward to working with her directly in the coming months to further accelerate our Best for All progress."

17:17 EST Masimo to acquire Sound United, terms not disclosed - Sound United, LLC announced that it has entered into a definitive agreement to be acquired by Masimo Corporation. "I have long been a fan (and proud owner) of Sound United's iconic brands and am honored to steward them through the next generation of technological evolution," Masimo Founder, Chair & CEO Joe Kiani commented. "Masimo shares Sound United's commitment to providing innovative, best-in-class products and experiences, with a relentless focus on improving the consumer experience." The transaction is expected to close near the middle of 2022, subject to the receipt of regulatory approvals and other customary closing conditions. Post-closing, Kevin Duffy will continue to lead Sound United, reporting directly to Masimo Chairman and Chief Executive Officer, Joe Kiani.

17:10 EST Talos Energy, EnLink Midstream to jointly develop CO2 capture solution - Talos Energy (TALO) and EnLink Midstream (ENLC) announced that they have executed a memorandum of understanding to jointly develop a complete CO2 capture, transportation and sequestration solution for industrial-scale emitters in Louisiana. The joint service offering will be focused on the Mississippi River corridor from New Orleans to Baton Rouge, which is one of the largest concentrated sources of CO2 emissions in the United States, and will utilize significant portions of EnLink's existing regional pipeline infrastructure of approximately 4,000 miles in Louisiana and Talos's recently-acquired River Bend CCS site in east Louisiana, as announced in a separate press release, which includes approximately 26,000 acres of pore space and provides sequestration capacity of over 500 million metric tonnes in the area. EnLink and Talos have begun to market the offering to potential customers.

17:05 EST West Fraser Timber commits to greenhouse gas reductions - West Fraser Timber "announced a commitment to set science-based targets to achieve near-term greenhouse gas reductions across all its operations located in the United States, Canada, United Kingdom and Europe. As the world's largest producer of lumber and oriented strand board and a leading manufacturer of other engineered wood and forest products, joining the Science Based Targets Initiative demonstrates the Company's commitment to sustainability leadership and contribution to global climate action. SBTi helps companies to set emission reduction targets in line with climate science and Paris Agreement goals. It promotes best practice in science-based target setting and independently assesses companies' targets. To accelerate corporate climate action, SBTi is focused on significant reductions in global emissions before 2030 and achieving net-zero emissions before 2050."

17:03 EST Ternium expects a sequential decrease in EBITDA in the Q1 - The company said, "Following an outstanding 2021, during which Ternium achieved record profitability and successfully completed its capacity expansion program, the company expects to deliver solid performance in 2022, despite a business environment with gradually normalizing steel prices and margins, supported by the ongoing ramp-up of the new hot-rolling mill in its Pesqueria facility. In the USMCA region, supply chain disruptions continue to affect several manufacturing industries' input procurement. For the automotive industry specifically, ongoing semiconductor scarcity is causing low unit inventory levels and significant pent-up demand. During 2022, Ternium anticipates this situation to gradually adjust and drive increased apparent steel demand in the region that, coupled with a decrease in steel imports, should cause declining steel prices to stabilize during the first half of the year. In Argentina, shipments remained at relatively stable levels during 2021, and the company expects this to continue in the first quarter, driven by healthy activity in the construction, agribusiness and automotive industries. The outlook for the Argentine market in 2022, however, remains significantly uncertain, given the unstable macroeconomic variables that persist in the country. Ternium expects a sequential decrease in EBITDA in the Q1, primarily resulting from lower margins, partially offset by higher shipments in the USMCA region."

17:00 EST Analog Devices raises quarterly dividend by 10% to 76c per share - The dividend is payable on March 8, 2022 to shareholders of record as of the close of business on February 25, 2022.

16:53 EST Caterpillar names William Schaupp chief accounting officer - According to a regulatory filing, on February 9, 2022, the Board of Directors of Caterpillar appointed William E. Schaupp as Chief Accounting Officer. Schaupp's appointment is effective April 1, 2022 and follows the previously announced retirement of Gary Michael Marvel as the company's Chief Accounting Officer. Schaupp has served as the company's Finance Director, Global Finance Services Division since August 2021. Prior to joining the company, Schaupp served as Vice President and Controller and Chief Accounting Officer from July 2018 to July 2021 and Assistant Controller and Acting Controller from April 2018 to July 2018 and Director Corporate Audit Services from January 2017 to April 2018 of PPG Industries, Inc.

16:49 EST Innospec sees outlook favorable to further sales growth - Patrick Williams, said, "We believe that Innospec's excellent Q4 performance leaves us well positioned for continued improvement in 2022. We exit the year with record quarterly sales and an outlook that we feel is favorable to further sales growth and margin expansion in all our businesses. We remain focused on working with our customers and suppliers to navigate the expected continuation of supply chain and inflationary challenges. Price actions have been announced in all businesses in the Q1 of 2022, and in parallel we continue to introduce innovative products which can help offset the impact of higher prices to our customers through enhanced performance."

16:47 EST Coherus Biosciences announces Paul Reider as chief commercial officer - Coherus BioSciences (CHRS) announced Paul Reider has been named chief commercial officer. Reider previously held the position of executive VP of commercial operations and market access. Reider has 30 years of biotechnology industry sales and marketing experience across oncology, rheumatology, endocrinology and rare disease therapeutic areas. Prior to joining Coherus in 2021, he served as VP of sales and strategic accounts for Puma Biotechnology (PBYI).

16:43 EST Altria says judge dismisses FTC claims against Altria, Juul - Altria Group announced that an Administrative Law Judge dismissed the Federal Trade Commission's claims against Altria and JUUL Labs, Inc. arising out of Altria's 2018 minority investment in JUUL. Following a three-week trial, the ALJ found that the evidence failed to sustain the alleged violations. The ALJ's decision is subject to review by the FTC. Any decision by the FTC may be appealed to any U.S. Court of Appeals. "We are pleased with this decision and have said all along that our minority investment in JUUL does not harm competition and does not violate the antitrust laws," said Murray Garnick, Executive Vice President and General Counsel, Altria.

16:41 EST Devon declares $1.00 per share fixed-plus-variable dividend, ups fixed dividend - Devon Energy announced its board of directors declared a record high fixed-plus-variable dividend of $1.00 per share based on Q4 financial performance. The dividend is payable on March 31 to shareholders of record at the close of business on March 14. As part of the Q4 dividend announcement, the board approved an increase in the fixed dividend of 45% or 5c per share. After the fixed dividend is funded, up to 50% of the excess free cash flow each quarter will be distributed to shareholders through the variable dividend.

16:36 EST Devon Energy sees Q1 production 560,000-580,000 boepd - Sees Q1 capital expenditures $540M-$610M. Sees Q1 tax rate 20%-25%.

16:33 EST Clearwater Paper says inflation expected to impact 2022 by $90M-$100M - Sees $120M-$140M impact in FY22 from previously announced price increases. Sees FY22 CAPEX of $60M-$70M.

16:31 EST Johnson & Johnson appoints Darius Adamczyk to board of directors - Johnson & Johnson (JNJ) announced that Darius Adamczyk, Chairman and CEO of Honeywell (HON), has been appointed to its Board of Directors.

16:25 EST Hookipa Pharma to develop arenaviral immunotherapy for HIV under Gilead pact - Hookipa Pharma (HOOK) announced it has entered into an amended and restated collaboration and license agreement with Gilead (GILD) to advance the development of a novel arenaviral immunotherapy as a component of a potential functional curative regimen for human immunodeficiency virus, or HIV. In April 2018, Gilead licensed exclusive rights to Hookipa's arenaviral platform to develop immunotherapies for HIV and hepatitis B virus, or HBV. Under those terms, the companies agreed to collaborate through a joint research phase, after which time Gilead had rights for further development. Under the amended and restated agreement, Hookipa is responsible for advancing the HIV program through the completion of a Phase 1b clinical trial, with funding from Gilead via an upfront payment and equity purchases. At the completion of the Phase 1b trial, Gilead has the exclusive right to assume further development of the program. The HBV portion of the agreement remains unchanged. Hookipa earned a one-time $4M preclinical milestone payment under the original 2018 collaboration and license agreement. Upon signing of the amended agreement, Hookipa will receive a payment of $15M. In addition, Gilead will make a $5M equity investment in Hookipa at a premium to the current market price, and up to an additional $30M of equity financing that can be drawn at Hookipa's discretion by December 31, 2023. "We are pleased to enter into this amended agreement with Gilead which includes provisions that we believe benefit both parties, and we hope ultimately the HIV community. Gilead is helping to advance our novel arenaviral platform technology, which has the potential to complement Gilead's overall research strategies for cures of HIV and HBV," said Joern Aldag, Chief Executive Officer at Hookipa.

16:21 EST Livent begins voluntary third-party assesment of its lithium operations - Livent announced that it has begun a voluntary, third-party assessment of its brine-based lithium extraction and manufacturing operations at the Salar del Hombre Muerto, Catamarca, Argentina. This independent assessment of the company's Fenix site is the next step in the multi-stage review against the Initiative for Responsible Mining Assurance, or IRMA, Standard for Responsible Mining. SCS Global Services, an IRMA-approved certification body, is conducting the third-party assessment, beginning with a desk review followed by an onsite audit.

16:21 EST Welltower, Reuben Brothers announce strategic partnership - Reuben Brothers and Welltower announced the formation of a long-term strategic partnership in conjunction with Reuben Brothers' acquisition of Avery Healthcare, one of Welltower's largest operating partners and the company's largest partner in the United Kingdom. The 50/50 joint venture partnership is expected to generate significant future growth opportunities through the development of the next generation of seniors housing properties by leveraging Reuben Brothers' real estate investment and development acumen and Welltower's unparalleled data analytics platform and leadership within the seniors housing industry. This transaction also positions Avery for superior growth to meet the demand of an aging population in the UK.

16:17 EST Acco Brands CFO Fenwick to retire this year - Acco Brands announced that Neal Fenwick, Executive Vice President and Chief Financial Officer, plans to retire this year after a 37-year career with the Company. A search for his successor is underway. Mr. Fenwick will remain active full-time until his successor is named and will assist with the transition.

16:17 EST Roblox down 13% in after-hours following earnings report - Roblox shares are down $9.65, or 13%, to $63.65 in after-hours trading following the company's Q4 report.

16:14 EST ViacomCBS added 9.4M global streaming subscribers in Q4 - Achieved 84% y/y growth in streaming subscription revenue.

16:09 EST Upstart announces $400M share repurchase program - Upstart announced that its Board of Directors has approved a share repurchase program with authorization to purchase up to $400M of common stock. "With the volatility in the trading of our stock, we have seen what we believe to be attractive buying conditions at various times over the past year, and our profitability puts us in a position to be able to initiate this program and take advantage of those situations on behalf of our shareholders," said Sanjay Datta, CFO of Upstart.

16:09 EST Airbnb: Impact of omicron has quickly dissipated

16:08 EST Airbnb reports Q4 nights and experiences booked 73.4M, up 59% y/y

16:07 EST Airbnb reports Q4 gross bookings value $11.3B

16:03 EST Wynn Resorts to sell real estate of Encore Boston Harbor for $1.70B - Wynn Resorts (WYNN) "announced that it has entered into a definitive agreement to sell all of the land and real estate assets of Encore Boston Harbor to Realty Income (O) for $1.70 billion in cash, representing a 5.9% cap rate. Wynn Resorts will continue to operate the property at the five-star standard for which the Company is renowned. Simultaneous with the closing of the transaction, we will enter into a triple-net lease agreement for Encore Boston Harbor with Realty Income. The lease will have an initial total annual rent of $100.0 million and an initial term of 30 years, with one thirty-year tenant renewal option."

15:36 EST JFrog up 3% as investor day continues - Shares of JFrog are up 83c, or 3%, to $26.53 in afternoon trading as the company's executive team hosts a Q&A session at the company's investor day meeting.

15:18 EST Timken wins contract as provider of high-precision drives for solar power plant - Timken announced it is providing high-precision drives for what will be the world's largest single-site solar power plant. Timken's solar-tracking technology, developed by its Cone Drive subsidiary, will be used to precisely position solar panels in line with the sun for the Al Dhafra PV2 site in Abu Dhabi, United Arab Emirates, or UAE. The Al Dhafra facility is expected to become fully operational in 2022. When complete, its 4M solar panels, controlled by 83,000 Cone Drive high-precision drives, are projected to power as many 160,000 homes across the UAE and reduce carbon dioxide emissions by approximately 2.4M metric tons annually.

14:36 EST Packaging Corp. VP Ridley sells $517K in company shares - Packaging Corp VP Bruce Ridley sold 3,481 shares of company stock at $148.60 per share on February 11, for a total transaction amount of $517,273.

14:19 EST NextPlay Technologies says metaverse project is 'ready for launch' - NextPlay Technologies said in a tweet that its first META Project and joint venture with SOMA Innovation Lab is "ready for launch." The company noted that the project was first announced in November 2021 and that interested users can now book a demo online. []:[https://twitter.com/NextPlayTech/status/1493664123476975618?s=20&t=sd5BFM0vhSE7CxEaLLnOww]

13:15 EST Ericsson reiterates commitment to investigate conduct in Iraq - Ericsson issued an update on Iraq media inquiries, stating in part: "In the past week, Ericsson has continued to receive detailed media inquiries from Swedish and international news outlets. Their interest pertains to information detailed in a 2019 internal investigation by the company, on conduct in Iraq. We are committed to transparency and continuously improving our compliance performance. Therefore, we are updating our earlier statement on this matter. We continue to invest significantly to understand these matters fully. As in all investigations we cannot exclude the possibility that we may not have found all the underlying facts. Ericsson takes any allegation of impropriety extremely seriously and welcomes any new facts brought to light as a result. This allows us to sharpen our processes further and target any wrongdoing. We reiterate our commitment to investigate and take action as appropriate to address any new information, in line with our Code of Business Ethics and under the terms of our 2019 Deferred Prosecution Agreement, with US authorities. With customers in more than 180 countries around the world, our products and services address critical communication needs for people and societies alike. We are committed to conducting business in a responsible manner, applying ethical standards in anti-corruption, humanitarian and human rights terms. We adhere to the United Nations' guiding principles on business and human rights - as well as all relevant international laws."

12:12 EST Netflix, Take-Two partner to produce 'BioShock' film adaptation - Netflix (NFLX) is partnering with 2K and Take-Two Interactive (TTWO) to produce a film adaptation of the renowned video game franchise "BioShock." "Across the titles' original releases as well as multiple re-releases, remastered editions and bundled collections, BioShock has sold more than 39 million copies worldwide, and is widely recognized as one of the most celebrated and beloved series in all of gaming," Netflix said. "The next installment is currently in development by Cloud Chamber." The Fly notes that the first "BioShock" game was released in 2007. Reference Link

12:07 EST PSEG raises quarterly dividend 5.9% to 54c per share - The board of directors of Public Service Enterprise Group declared a quarterly common stock dividend for the first quarter of 2022 of 54c per share payable on March 31, 2022 to shareholders of record on March 10, 2022. This action, which was announced during PSEG's September Investor Conference, represents a 3c per share, or 5.9% increase in the company's quarterly common stock dividend and brings the indicative annual dividend rate to $2.16 per share. Ralph Izzo, Chairman, President and Chief Executive Officer, said, "We are pleased to be able to increase the cash return to our shareholders. This latest increase represents the 18th increase in the common dividend in the past 19 years and marks our 115th consecutive year of paying a common dividend to shareholders, which is an achievement attained by very few companies. PSEG's long history of paying a common dividend is aided by our strong balance sheet, improved business mix and the durability of our growth strategy, which are expected to support consistent and sustainable growth in the common dividend."

12:00 EST Direxion Daily Semiconductor Bear 3X Shares falls -13.2% - Direxion Daily Semiconductor Bear 3X Shares is down -13.2%, or -62c to $4.11.

12:00 EST TAL Education rises 21.9% - TAL Education is up 21.9%, or 68c to $3.79.

12:00 EST Virgin Galactic rises 27.3% - Virgin Galactic is up 27.3%, or $2.22 to $10.36.

11:57 EST Hillstream BioPharma treatment of uveal melanoma granted orphan designation - Hillstream BioPharma's salinomycin was granted FDA orphan designation as a treatment of uveal melanoma, according to a post to the agency's website. Reference Link

11:50 EST MDV Stock trading resumes

11:40 EST US Foods says Sachem Head declined director offer without engagement - US Foods issued a statement in response to a press release from Sachem Head Capital Management, which disclosed its attempt to seek control of the board of directors through the nomination of seven directors for election to the company's ten-member board at its 2022 annual meeting, stating in part: "Since Sachem Head filed its Schedule 13D in respect of US Foods on October 7, 2021, members of our Board and management team have engaged with seriousness and urgency and had numerous discussions with Sachem Head. We approached these discussions with an open mind and a willingness to work constructively. In December, the Board's Nominating and Corporate Governance Committee interviewed each of the three director candidates Sachem Head privately proposed. Following these interviews and associated due diligence, we offered to appoint two new directors to the Board, including Scott Ferguson, Sachem Head's principal, and a mutually agreed-upon second director with relevant supply chain leadership experience. Sachem Head made the appointment of Bernardo Hees as Executive Chairman a precondition for any engagement. In the course of its evaluation of Bernardo Hees, the Board identified significant concerns regarding his leadership roles at previous companies, which Mr. Hees was unable to dispel during the interview process. As a result, the Board was not willing to appoint him to the Board, let alone name him Executive Chairman as originally proposed by Sachem Head... At US Foods, we believe that integrity in leadership matters. Mr. Hees' interviews did not allay the Board's concerns about Mr. Hees' oversight and leadership that resulted in these financial improprieties... We recognize there is more work to do and are committed to listening to all our shareholders as we drive the business forward. We have substantial opportunities ahead and look forward to discussing our plans and progress on our upcoming earnings call."

11:07 EST Teck Resources to pilot electric transport truck at HVC operations - Teck Resources and MEDATech announced the pilot of a fully electric on-highway transport truck to haul copper concentrate, marking the first use of a battery-electric truck to haul copper concentrate worldwide. The truck will travel between Teck's Highland Valley Copper Operations in south-central British Columbia and a rail loading facility in Ashcroft, B.C. This pilot of the MEDATech ALTDRIVE-powered fifth-wheel Western Star will help to advance Teck's goal of displacing the equivalent of 1,000 internal combustion vehicles by 2025. It will also provide valuable learnings for the electrification of Teck's vehicle fleet on the path to achieving the company's goal of reducing the carbon intensity of its operations by 33% by 2030 and becoming a carbon-neutral operator by 2050. The pilot is expected to begin in summer 2022 and is projected to eliminate 418 tonnes of CO2 annually - the equivalent of approximately 90 passenger cars - for the first pilot vehicle, while also reducing costs through fuel savings and reduced maintenance.

11:03 EST Horizon Therapeutics announces results from post-marketing safety analysis - Horizon Therapeutics announced results from a new post-marketing safety analysis of hearing events associated with TEPEZZA for the treatment of Thyroid Eye Disease. These findings, along with data on the sustainability of response to TEPEZZA, were presented at the 48th Annual Meeting of the North American Neuro-Ophthalmology Society, Feb. 12-17, in Austin, Texas. TEPEZZA is the first and only medicine approved by the U.S. Food and Drug Administration for the treatment of TED - a serious, progressive and potentially vision-threatening rare autoimmune disease.1 Since the FDA approval in 2020, Horizon has conducted post-marketing monitoring to understand the overall safety profile of TEPEZZA, including hearing-related events. Among the thousands of patients included in this 19-month analysis, approximately 10% of all cases reported to the safety database have included a hearing-related event. The most frequently reported hearing event was hypoacusis, followed by tinnitus. The mean age of the patient, where known, was 59.3 years. No new safety concerns were observed in the post-marketing database.2 This is comparable with what was seen in the pooled OPTIC Phase 3 and OPTIC-X open-label extension trials for TEPEZZA. Hearing-related adverse events were reported in 9.5% of patients treated with TEPEZZA, which were mild or moderate in severity, versus 0% of patients who received placebo. Adverse events experienced in the clinical trials were manageable, with few discontinuations or therapy interruptions. A separate analysis presented at NANOS 2022 examined the sustainability of response to TEPEZZA over the follow-up periods from the Phase 2 and OPTIC Phase 3 clinical trials and the OPTIC-X open-label extension study. A total of 121 patients were analyzed, with 9 patients receiving additional medications and/or surgery during the follow-up periods. Of those with data available, the majority of patients treated with TEPEZZA were proptosis, diplopia and European Group on Graves' Orbitopathy composite outcome responders up to 51 weeks after their last infusion.

11:02 EST Keysight, Samsung sign MOU to advance research, development of 6G tech - Keysight Technologies (KEYS) announced that the company has signed a memorandum of understanding with Samsung Research (SSNLF) to advance research and development of 6G technology, the next generation of wireless communication. Keysight joined forces with Samsung, to support the company's 6G vision of a hyper-connected world. 6G is expected to be built on technologies such as artificial intelligence (AI), sensing, digital twins, time-sensitive networking and holographic communications. The two companies will work together to develop test and verification technologies for 6G wireless systems.

10:26 EST Wesco: Supply chain constraints presents 'some uncertainty'

10:23 EST Wesco sees FY22 adjusted EBITDA margin 6.7%-7%

10:04 EST Pfizer announces EMA approval of 20-valent pneumococcal conjugate vaccine - Pfizer announced that the European Medicines Agency has approved the company's 20-valent pneumococcal conjugate vaccine, which will be marketed in the European Union under the brand name APEXXNAR. The vaccine is approved for active immunization for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae in individuals 18 years of age and older. Today's authorization follows the recent positive opinion from the EMA's Committee for Medicinal Products for Human Use announced on December 17, 2021. The authorization is valid in all 27 EU member states plus Iceland, Lichtenstein, and Norway. The EMA had previously accepted review of Pfizer's Marketing Authorization Application for the 20-valent pneumococcal conjugate vaccine candidate in February 2021. The EMA authorization for APEXXNAR is based on evidence from a clinical program in adults, including Phase 1 and 2 trials, and three Phase 3 trials describing the safety and evaluating the immunogenicity of the vaccine. More than 6,000 adult subjects 18 years and older participated in the three Phase 3 trials, including adults 65 years of age and older. The populations included adults with stable chronic medical conditions, pneumococcal vaccine-naive adults, and adults with a history of prior pneumococcal vaccination.

10:01 EST JetBlue adds 30 Airbus A220s to order book - JetBlue (JBLU) announced an agreement to exercise its option to add 30 additional Airbus (EADSY) A220-300 aircraft to its order book, bringing the total number of A220s in the airline's fleet and on order to 100. The aircraft's strong economics and operational performance are a key to JetBlue's long-term cost performance, while also enabling more sustainable flying, greater flexibility to support JetBlue's network strategy, and the introduction of its all-new onboard experience to more customers.

10:00 EST Daily S&P Biotech Bear 3x Shares falls -10.3% - Daily S&P Biotech Bear 3x Shares is down -10.3%, or -$4.09 to $35.55.

10:00 EST Virgin Galactic rises 13.4% - Virgin Galactic is up 13.4%, or $1.09 to $9.23.

10:00 EST Joby Aviation rises 15.1% - Joby Aviation is up 15.1%, or 72c to $5.48.

09:47 EST Dingdong falls -8.5% - Dingdong is down -8.5%, or -63c to $6.80.

09:47 EST Arch Resources rises 10.1% - Arch Resources is up 10.1%, or $11.44 to $124.70.

09:47 EST Joby Aviation rises 10.5% - Joby Aviation is up 10.5%, or 50c to $5.26.

09:42 EST Intergrated Media Technology Ltd trading resumes

09:37 EST Intergrated Media Technology Ltd trading halted, volatility trading pause

09:34 EST Hallador Energy, Hoosier Energy enter agreement to transfer ownership of Merom - Hallador Energy Companym through its new subsidiary Hallador Power Company, LLC, will acquire Hoosier Energy's 1-Gigawatt Merom Generating Station, located in Sullivan County, Indiana, in return for assuming certain decommissioning costs and environmental responsibilities. The transaction, which includes a 3.5-year power purchase agreement, is scheduled to close in mid-July 2022 upon obtaining required governmental and financial approvals. Per the agreement, Hoosier will purchase 100% of the plant's energy and capacity through May 2023, reducing purchases to 22% of energy output and 32% of its capacity beginning in June 2023 and through 2025. The companies' existing renewable PPA - signed in May 2021 and representing 150 MW of solar generation and 50 MW of battery storage - will be retained, with its start date delayed until Merom's eventual retirement. In January 2020, Hoosier Energy announced a new Long Range Resource Plan, which included the expected retirement of Merom in May 2023. Hoosier said at the time it would sell the plant if the right deal came to fruition. After entertaining interest from a number of different parties, the company found a unique partner in Hallador, which is able to operate the plant at a much lower cost given ownership and control of fuel supply. Hoosier will retain approximately 5,760 acres of land, which has potential for diverse economic redevelopment. Other benefits include elimination of millions of dollars in costs for plant decommissioning and long-term grounds maintenance. The new PPA provides additional capacity to Hoosier as well, another important element of the deal.

09:30 EST T2 Biosystems announces amendment, extension of CRG term loan agreement - T2 Biosystems announced the successful amendment and extension to its Term Loan Agreement with CRG Servicing LLC. The amendment extends both the interest-only period and the maturity date by one year from December 31, 2022 to December 31, 2023. No other material amendments were made to the Term Loan Agreement.

09:28 EST Entravision teams with Roku as streamer's media advertising partner in Mexico - Entravision (EVC) announced that the Company has partnered with Roku (ROKU), to serve as Roku's media advertising partner in Mexico. Entravision will help brands effectively reach consumers by advertising on the Roku streaming platform. As more consumers are moving to TV streaming, advertisers can reach them by moving budgets into TV streaming. Through Roku's advertising solutions, brands and marketers can reach audiences at scale on the Roku platform. Entravision, as Roku's trusted partner, will serve as an advertising partner in Mexico to work with brands interested in advertising through the Roku platform. "Entravision is very excited to partner with Roku, the pioneer in television streaming, as they begin advertising in Mexico," said Juan Saldivar, Entravision's Chief Digital, Strategy and Accountability Officer. "Through our partnership, Entravision will be able to connect brands and marketers in Mexico with Roku's advertising solution, in order to reach TV streamers on the Roku streaming platform." Saldivar continued, "Entravision has extensive digital marketing expertise for companies looking to tap into growing Latino audiences, including in Mexico. We look forward to leveraging our expertise and local market connections to support Roku's global advertising growth."

09:24 EST Dolphin Entertainment takes ownership position in FanJolt - Dolphin Entertainment has taken an ownership position in FanJolt, a new online, experiential platform creating interactions between fans and a curated list of talent to support their favorite causes. FanJolt offers fans the opportunity to speak directly with their favorite celebrity during live broadcasts. Dolphin manages all aspects of creative, publicity and marketing for the platform through its network of agencies and will facilitate talent and commercial relationships within the entertainment industry.

09:21 EST AeroVironment awarded $8.54M DoD contract - AeroVironment announced it received a $8.54M firm-fixed-price U.S. Department of Defense Foreign Military Sales, or FMS, contract award on January 27 to provide Puma 3 AE small unmanned aircraft systems, or UAS, initial spares packages, training and support to an allied nation. Delivery is anticipated by November.

09:18 EST CareCloud announces redemption of $20M Series A preferred stock - CareCloud announced that it is redeeming 800,000 shares of its 11% Series A Cumulative Redeemable Perpetual Preferred Stock, representing approximately 15% of the approximately 5,300,000 issued and outstanding shares of Series A Preferred Stock with a total liquidation preference of $20,000,000. The Redeemed Shares will be redeemed at a cash redemption price of $25.00 per share, plus any accrued and unpaid dividends up to, but not including, the redemption date of March 18, 2022 in an amount equal to $0.1375 per share, for a total payment of $25.1375 per share. From and after the Redemption Date, dividends on the Redeemed Shares will cease to accumulate, the Redeemed Shares will no longer be outstanding, and all rights of the holders of such shares will terminate, except the right of the holders to receive the cash payable upon such redemption, without interest. Regular dividends on the outstanding shares of Series A Preferred Stock of $2.75 per share will be paid separately on March 15, 2022 to holders of record as of the close of business on February 28, 2022, in the customary manner. Accordingly, the redemption price for the Series A Preferred Stock will not include such dividends, but it will include a partial month dividend from March 1, 2022 up to, but not including, the Redemption Date.

09:17 EST Citius receives FDA permission to proceed with Halo-Lido for hemorrhoids study - Citius Pharmaceuticals announced that the FDA has issued a Study May Proceed letter for Halo-Lido for the treatment of hemorrhoids. The Company is addressing recommendations made by the FDA and anticipates initiating a Phase 2b clinical study in the first half of 2022. Halo-Lido is a proprietary topical formulation of halobetasol and lidocaine that is intended to provide symptomatic relief to individuals suffering from hemorrhoids. Hemorrhoids are a gastrointestinal disorder characterized by pain, swelling, itching, tenderness, and bleeding.

09:15 EST Sunshine Biopharma announces pricing of $8M public offering, uplisting - Sunshine Biopharma announced the pricing of its underwritten public offering of 1,882,353 units at a price to the public of $4.25 per unit, for aggregate gross proceeds of $8 million, prior to deducting underwriting discounts, commissions and other estimated offering expenses. Each unit consists of one share of common stock, par value $0.001 per share, and two warrants, each warrant exercisable for one share of common stock. The common stock and warrants are immediately separable from the Units and will be issued separately. The warrants are exercisable immediately, expire five years from the date of issuance and have an exercise price of $4.25. In addition, the Company has granted Aegis Capital Corp. a 45-day option to purchase additional shares of common stock and/or warrants equal up to 15% of the number of shares and warrants, respectively, sold in the offering solely to cover over-allotments, if any. The purchase price to be paid per additional share of common stock will be equal to the public offering price of one unit , less the underwriting discount. The purchase price to be paid per additional warrant will be $0.01. If Aegis exercises the option to purchase only such warrants, additional proceeds will be nominal. If Aegis exercises the option in full for common stock and warrants, the total gross proceeds of the offering including the overallotment are expected to be approximately $9.2 million before deducting underwriting discounts and commissions and offering expenses. The offering is expected to close on or about February 17, 2022, subject to customary closing conditions. The Company also announced that, in connection with the offering, its common stock and warrants have been approved for listing on the Nasdaq Capital Market and will begin trading on the Nasdaq Capital Market under the symbols "SBFM" and "SBFMW" on February 15, 2022. Aegis Capital Corp. is acting as sole book-running manager for the offering.

09:13 EST Andretti expands relationship with KULR Technology - KULR Technology Group has joined five-time Indy 500 championship winning team, Andretti Autosport, to serve as the primary sponsor of Marco Andretti's No. 98 Honda for the 106th Running of the Indianapolis 500 Presented by Gainbridge. The 2022 Greatest Spectacle in Racing will mark the third-generation driver's 250th INDYCAR career start. KULR Technology Group first joined Andretti Technologies, the advanced technology arm of Andretti Autosport, and sister team, Andretti United Extreme E, in 2021 as the official thermal management and battery safety technical partner. The goal of the ATEC partnership focuses on transferring aerospace knowledge onto the racetrack. KULR's expertise with lightweight, high-performance thermal management solutions through space exploration provides the opportunity to implement new cooling technology, battery cell architecture and testing methodologies within the high performance and high-power applications across the motorsport landscapes.

09:11 EST Motorsport Games announces Next Gen car for NASCAR 21: Ignition - Motorsport Games announces the addition of NASCAR's Next Gen car to NASCAR 21: Ignition, the officially licensed video game. The Next Gen car update will be available starting Thursday, February 17, 2022 within a new "Test Drive mode" for players on all platforms. "Our development team couldn't be happier about adding Next Gen cars to the current iteration of Ignition, especially prior to the kickoff of the 2022 NASCAR season," said George Holmquist, Vice President of Publishing and Marketing at Motorsport Games. "We have shared in the excitement of our players and NASCAR fans with this highly anticipated game addition. We made sure to recreate the Next Gen car as close to its real-life counterpart as possible and we can't wait for everyone to get acclimated with driving the newest stock car in-game, just like the drivers will be throughout the year."

09:09 EST XFuels completes audit of historical financial statements - Xfuels announces the completion of an external accounting audit of its 2019 and 2020 financial statements. The finalization of this audit lays a foundation for Xfuels to once again have its common shares freely traded in Canada, and for Xfuels to qualify to file as a fully reporting issuer with the United States Securities and Exchange Commission. Further, Xfuels now expects to qualify for listing on OTC Markets Group's OTCQB Venture Market in the United States.

09:08 EST GenTech announces expansion of retail footprint for Fizzique - GenTech Holdings is proud to announce that its retail footprint for its brand Fizzique has now embarked on an exciting new era of growth with orders from several national retailers and regional health store power houses. With its first orders coming from UNFI for various retail chains that will soon be unveiled, these exciting new orders are being dispatched nationwide from York, PA through Greenwood, IN to Riverside CA. As well, Kingdom Nutrition Hutton Texas are to receive their first inventory of Fizzique within 10 days with Max Muscle in Modesto, CA receiving their inventory last week. Online retailer Muscle and Strength are also in the process of adding all four of the Fizzique flavors to their website after having placed a significant order for the product and customers are expected to be able to place orders online by the end of this week.

09:07 EST Hims & Hers announces partnership with GNC - Hims & Hers announced a partnership with health and wellness brand GNC to offer consumers health and wellness solutions at select GNC stores nationwide as well as online at GNC.com. Hims & Hers hair care offerings are now available on GNC.com and select stores.

09:06 EST CVS Health simplifies access to at-home COVID-19 test kits - Starting Feb. 15, eligible CVS Health consumers can visit CVS.com or the CVS App to utilize a new digital service that simplifies the process for locating, ordering, and picking up at-home COVID-19 test kits with zero upfront out-of-pocket cost and without the need for the consumer to submit a claim to their health insurance provider. Consumers can enter their insurance information when checking out online and CVS Pharmacy will process the claim with the individual's health insurance provider on their behalf. Consumers will receive email or text message notifications with updates on their order status, including when to head to a participating CVS Pharmacy location for fast and easy store pickup using their name and order number. Members of select insurance plans may also access tests with no up-front cost by visiting the pharmacy counter at their local CVS Pharmacy.

09:05 EST Silvergate Capital expands Silvergate Exchange Network to include euros - Silvergate Capital announced Euro SEN, an expansion of the Silvergate Exchange Network to enable customers to transfer euros in near real-time, 24 hours a day, 7 days a week. "The SEN, which recently crossed $1T in cumulative payment volumes, is integral to the everyday operations of our digital currency customers," said Alan Lane, chief executive officer of Silvergate. "The launch of Euro SEN is an extension of our commitment to building a superior payments platform, and we are excited that our customers can now move euros 24/7 just as they do U.S. dollars." Euro SEN was built using the same technology as the existing U.S. dollar SEN payment rails and enables customers to send euros to other Silvergate customers with immediate access to funds. Additionally, customers can seamlessly convert euros to and from U.S. dollars in near real-time. The technology, which is accessible through Silvergate's proprietary API and its online banking platform, allows digital currency exchanges and institutional investors to limit exposure to overnight price fluctuations around the world and take advantage of additional trading opportunities.

09:05 EST Freddie Mac announces automated assessment of direct desposit income - Freddie Mac announced that the company will launch a new, automated capability that allows mortgage lenders to assess a prospective homebuyer's income paid through direct deposit to reduce the paper documentation burden on borrowers so they can close loans faster and simplify the lending process. This income assessment solution is available to mortgage lenders nationwide through Freddie Mac's Loan Product Advisor asset and income modeler. AIM for income using direct deposits provides these cost-saving efficiencies, while continuing to meet Freddie Mac's strong credit underwriting standards.

09:05 EST CarGurus' CarOffer reaches milestone of 10,000 enrolled dealer rooftops - CarOffer, part of the CarGurus network, announced it has enrolled 10,000 dealer rooftops on its automated instant wholesale vehicle trade platform. The benchmark comes two and a half years after launching its Buying Matrix platform. "It's hard to believe that CarOffer's first transaction was only two and a half years ago," said Bruce Thompson, Founder and CEO of CarOffer. "When we launched the product, we weren't sure how quickly dealers would adopt an inventory trading platform completely foreign to anything they had ever encountered. That said, it was evident the industry needed a radical change, as decades-old inventory sourcing and liquidation methods were inefficient, manual and time intensive. So, we put everything on the line to create a platform that is one of a kind. I am so proud of the CarOffer teammates who have supported our vision from the very beginning, as this milestone would not have been possible without their ambitions and tenacity. We always had lofty aspirations but enrolling 10,000 dealer rooftops this early in 2022 exceeded even our highest expectations. I owe everything to the incredible team we have built and truly believe this is the only group of individuals that could have pulled off this significant achievement."

09:04 EST Rigetti Computing announces commercial availability of 80-qubit quantum system - Rigetti Holdings announced the commercial availability of its 80-qubit quantum system, Aspen-M. The system is available to the company's direct and distribution customers through Rigetti Quantum Cloud Services. Rigetti also reported results of system speed tests run on Aspen-M.

09:02 EST Grubhub launches Grubhub Goods brand nationwide - Grubhub announced national availability of its branded convenience concept, Grubhub Goods. Grubhub now offers on-demand convenience delivery to diners from more than 3,000 Grubhub Goods locations across the country. This nationwide expansion is in collaboration with 7-Eleven and follows a successful pilot in New York of more than a dozen Grubhub Goods locations offered with 7-Eleven in Manhattan. The Grubhub Goods locations with 7-Eleven reach the vast majority of Grubhub's diners nationwide and feature a selection of 7-Eleven's most popular convenience items, including energy drinks, ice cream, personal care products and more delivered by Grubhub drivers.

08:57 EST FactSet announces commencement of senior notes offering - FactSet Research Systems announced the commencement of an offering of a series of five-year senior notes and a series of ten-year senior notes pursuant to an effective shelf registration statement filed with the U.S. Securities and Exchange Commission. The Notes will be senior unsecured obligations of FactSet Research Systems Inc. FactSet intends to use the net proceeds of the offering, together with borrowings under its proposed new senior unsecured credit facilities and cash on hand, to finance the consideration for the proposed acquisition of CUSIP Global Services from S&P Global Inc. refinance FactSet's existing credit facilities and pay transaction fees related to the proposed CGS Transaction.

08:55 EST Sportradar enters multi-year agreement with USFL - The United States Football League, USFL, a new professional football league launching in April, announces a foundational partnership with Sportradar. The multi-year agreement, reached following a competitive bid process, establishes Sportradar as the Official Sports Data Partner of the USFL and the league's official integrity partner. Under terms of the agreement, Sportradar will develop new data collection and delivery systems for the league and its related businesses, including media and gaming, and will provide data to betting operators advertising during USFL telecasts. Additionally, as the league's official integrity partner, Sportradar will conduct bet monitoring and reporting via its Universal Fraud Detection System. "The fast, accurate and reliable data that Sportradar provides to the marketplace will be crucial to the USFL engaging its audience as the league establishes itself on the American sports landscape," said Ed Blonk, Chief Commercial Officer, Sportradar. "And, with the backing of Sportradar's industry-leading integrity services, the USFL is taking a proactive step to protect its brand and safeguard the league from match-fixing and betting-related corruption."

08:54 EST Conduent awarded three 8-year contract renewals from NY tolling authorities - Conduent Transportation, a global business unit of Conduent Incorporated, announced it was awarded three 8-year contract renewals from the tolling authorities of New York, NY, to provide upgraded E-ZPass account management systems, as well as license plate identification solutions for the state's Tolls by Mail program. The contracts support the Metropolitan Transportation Authority, MTA, Bridges and Tunnels, the New York State Thruway Authority, NYSTA, and the Port Authority of New York and New Jersey, which, when combined, oversee the largest tolling operation in the United States. "We're honored that the New York Authorities have again placed their trust in our Conduent team to maintain their critical solution needs for reliable, accurate financial and account management systems. We are thrilled to extend our three-decades-long partnership with the state," said Mark Brewer, President, Transportation Solutions at Conduent. "This award represents confidence in our global strategy to deliver modern transportation solutions as we provide smart technologies to benefit the environment and create improved driving experiences for millions of travelers." Conduent will provide modernized transaction processing, account management and financial management systems, as well as integrated invoice mailing, payment processing, and license plate identification solutions and services for customers. Pending federal approval, it will also support the country's first congestion pricing program when launched in New York City.

08:53 EST Rigetti Computing, Nasdaq team-up to pursue quantum applications - Rigetti Computing (RGTI) announced a collaborative agreement with Nasdaq (NDAQ) to pursue the development of quantum applications to help solve high-impact computational problems in the financial industry. The efforts will be powered by Rigetti Quantum Cloud Services, featuring Rigetti's 80-qubit "Aspen M" series quantum processor - the quantum computing industry's first commercial multi-chip processor. "We believe quantum computing has enormous potential for the financial industry and that our Aspen-M series processor is capable of providing the performance, speed, and scale necessary to help forward-leaning companies like Nasdaq adopt quantum computing technology and apply it to critical computational problems," said Chad Rigetti, founder and CEO of Rigetti. "Nasdaq is a remarkably innovative company that has consistently used new technology to stay ahead and transform their business. Their pioneering industry leadership is a perfect match for us." Rigetti and Nasdaq will work together to evaluate financial applications that may benefit from the ability of quantum computing to solve computational problems with improved accuracy, speed, or cost. Rigetti announced in October it has entered into a definitive merger agreement with Supernova Partners Acquisition Company II (SNII), a publicly traded special purpose acquisition company.

08:50 EST Marriott: Too much uncertainty to give specific RevPAR, earnings guidance

08:49 EST Advent Technologies awarded $2.2M in new contracts - Advent Technologies announced the signing of new contracts with manufacturers of clean power generation and energy storage solutions for the delivery of electrochemistry components. The contracts were signed in Q4 and have a combined value of $2.2M. Advent began delivering electrochemistry components in Q4 and deliveries are expected to continue through September. The vast majority of the new business is from North American based customers.

08:48 EST Marriott sees FY22 gross rooms growth approching 5%, deletions 1%-1.5%

08:48 EST QualTek Services begins trading on Nasdaq under the symbol 'QTEK' - QualTek Services announced that it has completed its business combination with Roth CH Acquisition III Co. (ROCR). The transaction was approved at a Special Meeting of Stockholders of Roth CH III held on February 14. On or about February 16, ROCR's units will cease trading, and QualTek's Class A common stock and warrants to purchase Class A common stock will begin trading on Nasdaq under the symbols "QTEK" and "QTEKW," respectively.

08:47 EST Abercrombie & Fitch launches associate-designed 'For Justice' collection - Abercrombie & Fitch is proud to announce the third installment of its "For Justice" collection. A gender-inclusive, purpose-led product capsule called "For Justice, For Growth," the collection was designed by members of Abercrombie & Fitch Co.'s BIPOC Associate Resource Group with the intention of amplifying Black voices throughout Black History Month and beyond. The collection is now available in stores and online at www.abercrombie.com for adults and www.abercrombiekids.com for kids. With pieces across the Abercrombie & Fitch and abercrombie kids brands, the collection's designs feature Abercrombie associates' own words, calling for unity, equity, the need to elevate Black voices, and respect both Black history and Black futures. Abercrombie will be donating $250,000 in anticipated proceeds from the collection's sales to The Steve Fund, the nation's premier organization dedicated to supporting the mental health and emotional well-being of young people of color. Abercrombie has partnered with The Steve Fund since 2020 as part of The Abercrombie Equity Project, the brand's initiative dedicated to social and racial justice.

08:47 EST Prologis appoints Tim Arndt as CFO - Prologis announced Tim Arndt will be the company's new CFO effective April 1. Arndt, who has been with Prologis since 2004, will succeed long-time CFO Tom Olinger, who plans to retire. A well-respected leader in the logistics real estate industry, Olinger has had a significant impact on Prologis and on the industry overall. Arndt is a seasoned finance leader with Prologis, having joined AMB in 2004 in portfolio management for the company's Strategic Capital business. Over his tenure, he has worked in several capacities, including as corporate treasurer, head of corporate planning and in the company's global deployment team. Previously, Arndt worked in real estate strategy at Gap Inc. and in debt capital markets at Forest City Enterprises. This change is the culmination of extensive preparation and a part of Prologis' ongoing leadership succession planning process. Olinger will remain with the company through the balance of the year as part of the transition plan. When he retires, he plans to focus full time on philanthropic causes.

08:45 EST Camber Energy majority-owned subsidiary Viking Energy closes acquisition - Camber Energy is pleased to announce its majority-owned subsidiary, Viking Energy Group, acquired on February 9, 2022 a 51% interest in two entities that own the intellectual property rights to fully developed, patent pending, ready-for-market proprietary Electric Transmission and Distribution Open Conductor Detection Systems. The purchase price for the interests acquired by Viking is up to $21,000,000, with $5,000,000 payable in shares of Viking on closing and the balance payable upon certain sales thresholds being achieved.

08:42 EST Marriott sees FY22 net rooms growth 3.5%-4% -

08:41 EST ION announces continued forbearance, amendment extension to credit facility - ION Geophysical Corporation announced that it has entered into a Second Forbearance and Sixth Amendment extension with PNC Bank, National Association, under its Revolving Credit and Security Agreement dated August 22, 2014 pursuant to which PNC has agreed to waive, through and including March 8, 2022, a cross default that would have occurred under the Credit Agreement by virtue of ION's missing and still not having paid, the interest payment on the 2025 Notes that was due on December 15, 2021. In addition, ION also announced that it had entered into Amendment No. 1 to the Forbearance Agreement with holders of more than 79% of its 2025 Notes to continue to forbear until March 8, 2022 from enforcing their rights and remedies arising as a result of ION's failure to make the December 15, 2021 interest payment due on the 2025 Notes. The forbearances are subject to the terms and conditions of the relevant agreements with PNC and the note holders, which are described in more detail in our current report on Form 8-K filed with the SEC. ION remains in continuing discussions with PNC and the holders of its 2025 Notes and other indebtedness regarding various strategic alternatives to strengthen its financial position and maximize stakeholder value. These strategic alternatives include, among others, a sale or business combination transaction or sales of assets, any of which may be executed as part of an in-court or out-of-court restructuring process.

08:41 EST MusclePharm announces partnership with Alliance Sales & Marketing - MusclePharm announced a national partnership with Alliance Sales & Marketing to help accelerate the growth of the Company's energy drink business. Alliance will leverage its industry knowledge and relationships to expand the MusclePharm and FitMiss line of energy drink products into grocery and convenience channels across the United States. Ryan Drexler, the Chairman of the Board and Chief Executive Officer of MusclePharm, stated, "We are excited to partner with an established company like Alliance to help our MP beverage team build out sales and distribution across the country of our energy drink lines, MP Combat Energy and FitMiss Energy. Alliance has a reputation as one of the best sales and marketing brokers in the business and will use their close, trusted relationships with both national and regional retailers to accelerate the growth and adoption of our brands. We believe our energy drink lines, now supported by an internal and external team of top industry veterans, has the potential to become a meaningful growth driver for our Company."

08:38 EST Aqua Metals on track to deploy future lithium-ion battery recycling operation - Aqua Metals has made significant progress in moving its economical and environmentally advantageous lithium-ion battery, LiB, recycling process from concept to execution to meet the growing global demand for lithium-ion battery recycling and supply chain needs. The Aqua Metals LiNiCo strategic alliance provides the venue for Aqua Metals to apply its AquaRefining process to LiB recycling in a commercial production facility. Aqua Metals' preliminary work has yielded promising results. LiNiCo is focused on developing and implementing its novel LiB crushing, separation, and extraction processes for lithium and graphite. Aqua Metals plans to process the black mass produced by LiNiCo and others to produce pure nickel, cobalt copper, and other key high-value compounds. The Company has already successfully lab-tested cobalt plating at its Innovation Center, yielding high purity cobalt. Aqua Metals is targeting a pilot circuit that will produce meaningful quantities of critical metals and compounds by late summer or early fall 2022. The two companies plan to combine their technologies in a 140,000 square foot LiNiCo plant in the Tahoe-Reno Industrial Center, to create a fully integrated recycling and refining operation with commercial production beginning and scaling by late 2022 or early 2023.

08:38 EST Ecolab sees FY22 EPS growth reaching low-teens levels - "We move into 2022 with strong business momentum. With very healthy sales growth, robust new business wins, new innovation and increased pricing, we expect to progressively compensate for higher delivered product costs and to drive strong earnings growth. While we expect a decent global economy, we also expect the COVID impacts to remain significant during the first half of the year, and we expect inflation to remain high before it progressively eases during the second half of the year. We expect these cost impacts to remain especially strong in the first quarter of 2022, even slightly higher than those experienced in the fourth quarter. We look for the first quarter to show healthy sales growth and a flattish year-over-year earnings per share comparison impacted by continued high raw material and freight costs. For the full year 2022, we believe our sales, pricing and cost efficiency actions will enable us to deliver continued strong sales gains with adjusted diluted earnings per share growth reaching low-teens levels, assuming once again that inflation and supply constraints ease as the year progresses. We continue to expect the impact of Purolite, including 26c per share of transaction-related amortization, will be neutral to 2022 adjusted diluted earnings per share. We remain confident in our long-term outlook as our value proposition to help solve the world's people, planet and business health needs is more important than ever. With our strong pricing and an inflationary environment that will ease ultimately and lead to higher margins, we expect to continue to leverage our robust growth opportunities to drive superior results for our customers and shareholders," noted the company

08:37 EST Legend Biotech announces FDA clinical hold on LB1901 trial - Legend Biotech announced that the company was informed by the FDA via e-mail communication that its Phase 1 clinical trial for LB1901 has been placed on clinical hold. LB1901 is the company's investigational autologous chimeric antigen receptor T-cell, or CAR-T, therapy targeting malignant CD4+ T-cells for the treatment of adults with relapsed or refractory T-cell lymphoma. The FDA indicated they will provide an official clinical hold letter to Legend Biotech by March 11. To date, one patient has been dosed in the clinical trial. Before receiving the FDA's clinical hold communication, Legend Biotech had, in accordance with the protocol, paused the clinical trial due to low CD4+ T-cell counts in the patient's peripheral blood and notified the FDA. The patient has not experienced drug-related serious adverse events, or SAEs, and is being monitored in accordance with the protocol.

08:36 EST NRx announces results of review of the TESICO trial - NRx Pharmaceuticals announced results of a review conducted by the Therapeutics and Prevention Data Safety and Monitoring Board, or DSMB, of the National Institute of Allergy and Infectious Diseases, or NIAID, of the National Institutes of Health, or NIH, on February 14. The DSMB reviewed data on 448 ICU patients with Critical COVID-19 Respiratory Failure who were enrolled in the ACTIV-3b, or TESICO, trial. The TESICO protocol was submitted by NIH and cleared by the FDA as a Phase 3 trial that, if positive, may be used in the submission of a New Drug Application for ZYESAMI. ACTIV-3b is a randomized, placebo-controlled clinical trial testing ZYESAMI and Veklury in hospitalized patients with acute respiratory failure due to COVID-19. The patients enrolled in TESICO are critically-ill patients in the ICU who have exhausted other approved therapies and require high-flow nasal oxygen, mechanical ventilation, or extracorporeal membrane oxygenation to maintain blood oxygen.

08:35 EST UGI, Global Clean Energy enter pact to distribute renewable LPG - UGI Corporation (UGI) announced that its subsidiary, AmeriGas Propane, has entered into an agreement with Global Clean Energy Holdings (GCEH) to purchase and distribute renewable LPG. AmeriGas will leverage its supply and logistics infrastructure and sales and marketing teams to market and distribute renewable LPG to new and existing customers primarily in the state of California. As part of a multi-year agreement, GCEH's Bakersfield biorefinery will process up to 15,000 barrels of renewable feedstock per day, including their proprietary energy crop - camelina, to produce renewable fuels including bioLPG. This biorefinery, which is expected to begin operations in the first half of calendar 2022, is projected to produce approximately 13M gallons of renewable LPG in its first year, making it the largest commercially available renewable propane production facility to date in the United States. Under the distribution partnership, AmeriGas will be the long-term exclusive buyer of renewable LPG from GCEH's Bakersfield biorefinery.

08:33 EST ClearSign Combustion provides update on progress for its products in China - ClearSign Technologies provided an update on commercialization progress for its products in China. The Company's 125hp fire tube boiler, which received certification in April 2021, has been sold to a customer and is scheduled for installation in a rental boiler by the customer for commercial deployment. The Company anticipates that this deployment will provide further benefit to ClearSign from the additional exposure the Company may receive from the demonstration of ClearSign's boiler burner technology to Chinese customers. The Company is on track to create a strategic sales channel and alliance through a Collaboration Framework Agreement with China's top tier boiler company Jiangsu Shuangliang Boiler, subsidiary of China's Shuangliang Group which is one of China's top 500 enterprises. The Company signed a new, updated and expanded Collaboration Agreement with the Beijing District Heating Group. This is a renewal and expansion from the original Collaboration Agreement that was entered into in May 2017 and updated in June 2019. The Beijing District Heating Group's entry into this new Collaboration Agreement confirms that it will continue its investment and support in ClearSign technology. Under the terms of the Collaboration Agreement, the Beijing District Heating Group agrees to work with the Company to both install and demonstrate the ClearSign Core innovative technology in its boilers following formal government certification

08:32 EST Zogenix supports new genetic testing program with UMDF - Zogenix announced that the company is sponsoring a new no-cost genetic testing program, the United Mitochondrial Disease Foundation, UMDF, Pilot Genetic Testing Project, in partnership with UMDF and Probably Genetic, to help patients obtain a confirmed genetic diagnosis of mitochondrial disease. The program is available to any eligible patient in the U.S. with a suspected diagnosis of mitochondrial disease. "Because mitochondrial diseases affect various organs and tissues, the path to diagnosis can be challenging and long," said Bradley Galer, M.D., Executive Vice President and Chief Medical Officer, Zogenix. "We are proud to offer no-cost genetic testing to help expand access to these much-needed genetic tests to shorten the diagnostic journey and help patients and their families seek appropriate care." The UMDF Pilot Genetic Testing Project will be a patient-initiated no-cost genetic testing program for patients with a suspected mitochondrial disorder.

08:31 EST China Xiangtai Food announces Nasdaq ticker symbol change to 'BTOG' - China Xiangtai Food announced that its ticker symbol on the Nasdaq Stock Market will change to "BTOG" effective at the open of market trading on Tuesday, February 15, 2022. China Xiangtai has traded under the ticker "PLIN" since the Company's initial public offering in 2019. "The ticker symbol 'BTOG' contains 'BT', indicating the meaning of 'bit' or 'blockchain', and 'OG', representing 'Origin' or the mindset of from past origin to a shared future for humankind." Ms. Zeshu Dai, Chief Executive Officer of the Company commented, "The management of the Company believes that the ticker symbol 'BTOG' is a more accurate reflection of our recently engaged business and operation in the cryptocurrency mining sector as we are looking forward to increasing our presence in the new business sector." No action is required from the Company's shareholders relative to the ticker symbol change. The Company's ordinary shares will continue to be listed on Nasdaq and the CUSIP will remain unchanged.

08:29 EST Hepion appoints Eddie Cheung to lead Strategic Medical Affairs in Asia - Hepion Pharmaceuticals announced that it has appointed Eddie Cheung to lead Strategic Medical Affairs in Asia. In this newly created role with Hepion, Dr. Cheung will explore and identify possible partnerships, and will liaise with national and regional regulatory authorities and thought leaders to advance rencofilstat's clinical development strategy in China and other parts of Asia.

08:27 EST Worksport completes all required testing on pre-production Terravis System - The company said, "Worksport has completed all required testing on the pre-production prototype of the Terravis System, including the Terravis SOLIS & Terravis COR energy storage systems. Management is keen to report that the supply chain is intact with no anticipated delays for the upcoming final production prototypes. Delays in receiving the prototype's removable batteries were a result of logistic failures from the shipper and were resolved by the end of 2021. We received the removable battery shipment just before Christmas and proceeded with testing immediately after the holidays. Having successfully undergone multiple testing phases with minimal changes needed, production for the Terravis System is scheduled to begin by the end of March 2022, with subsequent deliveries to reservation holders in Q2 2022. The Terravis System's overall design outperformed the expectations of internal electrical engineering teams. Features such as advanced hot swapping performed as expected, system efficiency was within the required margin of error, and the inverter output an actual pure sine wave, highlighting energy quality that's notably better than competitors."

08:24 EST OptimizeRx introduces new key performance indicators - OptimizeRx has developed relevant KPIs that best represent its "land and expand" strategy within key customer accounts and overall scalability of its business model. The KPIs being introduced are representative of the Company's penetration within the top 20 largest pharmaceutical manufacturers, net revenue retention and revenue per employee. Ed Stelmakh, CFO and COO at OptimizeRx commented, "We believe these KPIs demonstrate our ability to execute and drive future growth of our business as we continue to gain momentum from our customers' increasing investments in technology-enabled, digital, patient-centric solutions. Our footprint in the top 20 pharmaceutical manufacturers positions us well to compete and win our share of the largest category of addressable commercial spend and we look forward to communicating our story in a transparent and measurable fashion."

08:22 EST Ebang launches Australian cryptocurrency exchange - Ebang International announced the official launch of Ebonex Exchange, the Company's cryptocurrency exchange in Australia, on February 15, 2022. Ebonex Exchange is a digital asset trading platform independently created and developed by the Company's technicians who are senior industry experts. The Company has launched its Australian operation with the establishment of its Sydney office in 2021. Dong Hu, Chairman and Chief Executive Officer of the Company, commented, "We believe that the mature business environment and rigorous regulatory regime in Australia will have a great positive impact on Ebonex Exchange's prospects. We expect that the cryptocurrency space is poised for significant growth as the market for trusted platforms has grown significantly during the last year. Our objective is to have the Ebonex Exchange become one of the premier markets in the cryptocurrency space and to become a trusted platform for cryptocurrency participants worldwide. The launch of Ebonex Exchange has opened up a whole new market for the Fintech industry and is yet another critical milestone in the Company's strategic development."

08:20 EST LifeMD launches primary care platform nationwide - LifeMD announced the full-scale national launch of its virtual primary care platform. The LifeMD primary care offering combines best-in-class technology with top-quality doctors across 50 states in one unique platform. It introduces a patient-first healthcare experience, giving patients a personalized relationship with a leading doctor whose expertise will be correlated with the patient's clinical needs. In November, LifeMD launched the platform in beta form, making it available by invitation as part of a sequenced rollout. At the time, Schreiber cited the "full-blown crisis" in primary care, noting that 25% of adults in the U.S. lack a primary care physician - and that even people who have one often wait months for an appointment. With today's launch, anyone in the U.S. can access LifeMD's primary care service through the website or the LifeMD app and then follow a simple three-step process: A health questionnaire, a virtual meet-and-greet consultation with their new primary care doctor, and ongoing 24/7 access to LifeMD's healthcare team, including management of prescriptions and the ability to make a virtual appointment at the click of a button.

08:19 EST PDS Biotechnology announces clinical trial with Mayo Clinic to study PDS0101 - PDS Biotechnology Corporation announced the initiation of an Investigator-Initiated Trial , MC200710, for PDS0101 alone or in combination with the checkpoint inhibitor, KEYTRUDA, in patients with HPV-associated oropharyngeal cancer at high risk of recurrence. The trial is being led by Drs. David Routman, Katharine Price, Kathryn Van Abel, and Ashish Chintakuntlawar of Mayo Clinic, a nationally and internationally recognized center of excellence for the treatment of head and neck cancers. HPV(+)OPSCC is now the most common type of head and neck cancer and has been increasing significantly in recent years. Oropharyngeal cancer is a disease in which cancer cells form in the tonsil tissues of the back and side of the throat. According to the National Cancer Institute, smoking or being infected with the human papillomavirus, especially HPV16, can increase the risk of oropharyngeal cancer. The American Cancer Society estimates there are over 54,000 new cases of oral and oropharyngeal cancer and over 11,000 related deaths in the United States, annually. The study treatment will be administered before patients proceed to transoral robotic surgery with curative intent. Treatment in this setting is referred to as neoadjuvant treatment. PDS0101 has been shown to induce killer T-cells that target and kill HPV-positive cancers, either alone or in combination with checkpoint inhibitors in preclinical studies, and in combination in clinical studies of patients with advanced recurrent/metastatic HPV-associated cancers. This study will explore whether PDS0101 with or without checkpoint inhibition may increase HPV-specific anti-tumor responses, potentially resulting in tumor shrinkage, pathologic regression, and decreases in circulating tumor DNA.

08:16 EST Shoals Technologies unveils eMobility Innovation Center at company headquarters - Shoals Technologies unveiled its eMobility Innovation Center at the company's headquarters in Portland, TN. "The 'living lab' displays Shoals' best in class EV charging and eMobility solutions. It enables customers to discover the company's "Fuel by Shoals" portfolio of products and solutions in person, and showcases how Shoals is disrupting the traditional ways in which EV charging infrastructure has been deployed.," the company said. "We are thrilled to unveil our eMobility Innovation Center here at our company's headquarters in Portland, Tennesee," said Jason Whitaker, Chief Executive Officer of Shoals. "Our goal is to deliver a more simple, reliable, and scalable way to deploy EV charging systems, and the eMobility Innovation Center provides the optimal demonstration of our technology, allowing customers to experience our eMobility solutions first hand."

08:14 EST InspireMD appoints Adnan Siddiqui as member of scientifc advisory board - InspireMD announced the appointment of Adnan Siddiqui, MD, PhD, FAANS, FACS, FAHA to the Company's Scientific Advisory Board. Dr. Siddiqui brings extensive knowledge and expertise to InspireMD as a neurovascular surgeon and clinical scientist focused on and dedicated to the comprehensive management of ischemic stroke and vascular diseases involving the brain and spinal cord. Dr. Adnan Siddiqui is Vice-Chairman and Professor of Neurosurgery at the State University of New York at Buffalo.

08:13 EST authID.ai joins Microsoft Partner Network - authID.ai announced that it has joined the Microsoft Partner Network and expanded Verified CloudConnect with the integration of its flagship facial biometrics solution to Microsoft Office 365 and Azure via Active Directory Federation Services. With a biometric selfie, Verified CloudConnect strengthens workforce identity authentication for Microsoft Office 365 and Azure users with strong multi-factor authentication.

08:12 EST Marrone Bio, Corteva enter new distribution contract - Growers in Europe will have access to a novel, sustainable option for enhancing plant health and crop quality through a new agreement between Pro Farm Technologies, a subsidiary of Marrone Bio Innovations, (MBII) and Corteva Agriscience (CTVA). Under the agreement, Corteva will be the exclusive European distributor for Kinsidro Grow, a novel, foliar bionutrient that delivers key nutrients resulting in increased plant vigor. Kinsidro Grow is a proprietary product developed by Pro Farm Technologies that optimizes nutrient conditions in plants resulting in improved plant health and crop quality. Through foliar application on crops during the vegetative growth stage, the bionutrient delivers better yields and more favorable returns on investment. Kinsidro Grow is also easy to use and compatible with a grower's current agronomic practices. This collaboration represents another step forward for Corteva's expanding global biologicals portfolio, which is dedicated to developing biostimulants, biofertilizers, bionutrients, biocontrol and pheromone products with proven, predictable performance. Kinsidro Grow will provide value through enhanced crop vitality and enhancing yield potential and sustainability, in line with the Corteva Agriscience 2030 Sustainability Goals. The multi-year agreement, which goes into immediate effect, applies to European row crops such as corn, soybeans, wheat, and cotton, and builds on the successful seed treatment agreement between both companies. In 2021, Pro Farm Technologies' novel micronutrient seed treatment and growth promoter, Lumidapt, was applied on more than 10 million Pioneer corn, winter rapeseed, and sunflower seed hectares.

08:09 EST BorgWarner secures contract with Chinese luxury new energy vehicle brand - BorgWarner has secured a contract with a Chinese luxury new energy vehicle brand to supply its new integrated drive module equipped with its compact 800V silicon carbide inverter and hairpin electric motor. The 800V iDM220 features BorgWarner's exclusive and compact Viper power module which is the core of the SiC inverter, helping improve the range, driving performance and safety of electric vehicles. This is BorgWarner's first 800V iDM project worldwide, opening a new chapter in the company's global electric drive business.

08:08 EST Wolfspeed CTO Dr. Palmour elected to National Academy of Engineering - The National Academy of Engineering has elected Wolfspeed, co-founder and Chief Technology Officer, CTO, Dr. John Palmour into the organization's 2022 class for the development of Silicon Carbide-based advanced electronic devices. Palmour was one of the graduate students from North Carolina State University who founded the company in 1987 with the belief that Silicon Carbide could enable superior semiconductor technology. With his knowledge and expertise, Palmour has helped Wolfspeed transform and evolve. Now, over 30 years later, the business has grown into a pure-play semiconductor powerhouse leading the industry transition from silicon to Silicon Carbide. "We all feel privileged to be working alongside John," said Wolfspeed Chief Executive Officer Gregg Lowe, "His passion and expertise with this transformational technology has led our team to groundbreaking innovation over the years and today is enabling us to help our customers reach new levels of energy efficiency."

08:07 EST GCM Grosvenor increase stock repurchase authorization to $45M - GCM Grosvenor's Board of Directors increased its stock repurchase authorization under the company's existing stock repurchase plan authorized on August 6, 2021 by $20 million, from $25 million to $45 million

08:06 EST Kohl's unveils location of 400 new Sephora at Kohl's shops - Kohl's announced the list of the 400 stores that will be adding Sephora at Kohl's shops this year. From Alaska to Maine, the 400 stores will span 36 states, eight of which are brand new homes to Sephora at Kohl's. The addition of 400 stores brings the Sephora at Kohl's location total to 600 and puts the partnership on track to meet its 850 store goal by 2023.

08:05 EST Kuke Music establishes a blockchain business unit - Kuke Music Holding announced that the Company has established a blockchain business unit and completed a strategic investment in KOLO, a leading international non-fungible token or NFT, platform for classical music in the Metaverse. Kuke's blockchain business unit aims to utilize blockchain technology to validate, authorize, and protect digital music copyrights. In addition, the Company's strategic investment in KOLO will further enable the development of a consumer-oriented, classical music-focused and global NFT application in the Metaverse.

08:04 EST Ardmore Shipping expects its sectors to continue a recovery in 2022 - Anthony Gurnee, the Company's CEO, commented: "Based upon clear and encouraging fundamentals, we expect our sectors to continue a recovery in 2022 from an already improved Q1 to-date, but also potentially influenced by many competing factors, including the evolution of the pandemic and the global economy, geopolitical concerns, and currently high oil prices impacting cargo movement and bunker costs. Notwithstanding these factors, the big picture is very much one of an ongoing economic recovery, rising tonne-mile demand, and a tight tonnage supply outlook aided by heightened tanker scrapping and a rush of newbuilding orders in other shipping sectors that has pushed tanker newbuilding prices up and delivery schedules out. Given this outlook, we have been increasing our spot exposure, while continuing a financially conservative stance in view of the potential cross currents in the market. Moving forward, Ardmore remains well positioned in terms of market upside and financial strength, with a high-quality modern fleet and a strong balance sheet."

08:01 EST Westhaven Gold reports drill results from Shovelnose gold property - Westhaven Gold announced drill results from its ongoing, fully-financed drill campaign at its 100% owned 17,623-hectare Shovelnose gold property. Shovelnose is located within the prospective Spences Bridge Gold Belt, which borders the Coquihalla Highway 30 kilometres south of Merritt, British Columbia. Westhaven is reporting assays for 20 holes from its ongoing drill campaign at Shovelnose. An additional 19 holes are in the lab pending assay as well. Westhaven currently has one drill turning at the FMN target which is approximately 1.5 to 2km northwest of the recently released South Zone in-pit resource. Mineralization at the FMN target has been encountered over a strike length of 480 metres starting at the top of bedrock. Vein Zone 1 broadens up-dip, near surface, with true widths of up to 40 metres as seen in hole SN21-188. Drilling at the FMN zone is targeting higher-grade mineralization at the preferred elevation range of 1200 to 1400m over an area extending southeast towards hole SN20-139 and northwest towards and beyond hole SN21-167. Recent Drilling Highlights: SNR21-48; 129.00 metres of 0.62 g/t gold and 2.10 g/t silver, including 4.00m of 6.04 g/t Au and 20.42 g/t Ag. SNR21-49: 124.00m of 0.41g/t Au and 2.23 g/t Ag, including 1.00m of 9.02 g/t Au and 11.85 g/t Ag. SNR21-49: 11.30m of 1.17g/t Au and 5.90 g/t Ag, including 5.00m of 1.74 g/t Au and 7.70 g/t Ag. SN21-189: 3.00m of 1.50g/t Au and 613.00 g/t Ag. Peter Fischl, Exploration Manager, comments: "Recent drill results at Shovelnose continue to define broad intervals of gold mineralization contained in Vein Zones 1 and 2 and associated halos in the northwestern portion of the proposed open pit at South Zone. These drill results are not included in the recently released open-pit resource of 1.1 million ounces gold-equivalent for South Zone. These broad intercepts confirm the bulk tonnage potential at South. This mineralization remains open to the northeast of hole SNR21-48, where Vein Zone 2 is interpreted to continue up-dip from this hole. Additional step-out holes are now being planned to test further to the NE along drill section S0166. Additional gold mineralization containing significant silver was intersected in hole SN21-189. This hole was testing a CSAMT target. The nature of this mineralization is currently being evaluated."

07:59 EST MoneyGram trading halted, news pending

07:51 EST Medigus' Charging Robotics, Ben-Gurion University to develop EV charging system - Medigus announced that its wholly-owned subsidiary, Charging Robotics and BGN Technologies, the technology transferred company of Ben-Gurion University, signed an agreement to develop the next generation of Charging Robotics' wireless charging system for electric vehicles. Once developed, the system will be installed on a dedicated robot that will reside under the vehicle and automatically and wirelessly recharge the battery. The system is designed to be installed in public parking lots in a manner that will lower the infrastructure installation costs compared to other available systems. "This system addresses a key problem in the EV marketplace identified by industry experts - vehicle sales are outpacing the installation of convenient charging stations," said Liron Carmel. CEO of Medigus. "According to a report by The Fuel Institute last June, 90 percent of EV owners have their own garages, but those numbers will change dramatically as city-dwellers are buying more EVs."

07:49 EST Theratechnologies launches internal field force - Theratechnologies announced it is launching an internal sales force. Paul Levesque, President and Chief Executive Officer, Theratechnologies, said, "We now possess the necessary critical mass to bring aboard a dedicated field force - as we aim towards advancing the growth of our commercial franchises. We have witnessed positive headwinds post-COVID, now that face to face meetings have resumed. This and other positive factors have led to the decision to transition from a contract field force model to one staffed by Theratechnologies employees. We are confident that hiring our own field sales and medical affairs colleagues will significantly improve the engagement and ownership of those charged with the important task of interacting with our customers. We fully expect this change will be a driver of future growth and will improve both the recruitment and retention of top talent as we begin this new chapter in the future of Theratechnologies. As we look to expand our sales and medical affairs organization, we are delighted to welcome key members of our contract field force into the Theratechnologies family."

07:48 EST Cytokinetics says omecamtiv mercabil had no effect on exercise capacity - Cytokinetics, Incorporated announced topline results from METEORIC-HF, a Phase 3 clinical trial of omecamtiv mecarbil in patients with heart failure with reduced ejection fraction. Omecamtiv mecarbil is an investigational, selective, small molecule cardiac myosin activator for the treatment of heart failure with reduced ejection fraction. METEORIC-HF evaluated the effect of treatment with omecamtiv mecarbil compared to placebo on exercise capacity as determined by cardiopulmonary exercise testing following 20 weeks of treatment in patients with HFrEF receiving standard of care therapy. The trial completed enrollment of 276 patients in June 2021. There was no effect on the primary endpoint, which was the change in peak oxygen uptake on CPET from baseline to Week 20 in patients treated with omecamtiv mecarbil compared to placebo. Adverse events, including major cardiac events, were similar between the treatment arms and the safety profile of omecamtiv mecarbil in METEORIC-HF was consistent with prior clinical trials including GALACTIC-HF. Results from METEORIC-HF will be presented at the American College of Cardiology 71st Annual Scientific Session & Expo, in a Late Breaking Clinical Trial session on Sunday, April 3, 2022 from 9:45-9:55 a.m. ET. "While medical therapies have demonstrated significant reductions in the risk of adverse clinical outcomes in heart failure patients with reduced ejection fraction, as was also observed with omecamtiv mecarbil in GALACTIC-HF, demonstrating an improvement in exercise capacity with these same medical therapies has been elusive," said Fady I. Malik, M.D., Ph.D., Cytokinetics' Executive Vice President of Research & Development. "These neutral results from METEORIC-HF may provide new insights into the role of cardiac function in determining exercise capacity relative to other potential contributors such as skeletal muscle dysfunction. We are grateful to the trial investigators, site personnel, patients and caregivers who participated in the METEORIC-HF, especially given challenges posed by the pandemic." Cytokinetics recently announced that the U.S. Food & Drug Administration has accepted and filed the company's New Drug Application for omecamtiv mecarbil. The NDA is supported by the results from GALACTIC-HF, the Phase 3 cardiovascular outcomes clinical trial of omecamtiv mecarbil that enrolled over 8,000 patients in 35 countries across 945 sites. GALACTIC-HF demonstrated a statistically significant effect of treatment with omecamtiv mecarbil to reduce risk of the primary composite endpoint of cardiovascular death or heart failure events compared to placebo in patients treated with standard of care. Additional analyses from GALACTIC-HF demonstrated a greater treatment effect of omecamtiv mecarbil in patients with lower left ventricular ejection fraction, as well as other characteristics that may indicate worsening heart failure.

07:48 EST Repligen launches AAV affinity resins for gene therapy purification - Repligen announced the commercial launch of three advanced affinity chromatography resins for use in gene therapy manufacturing workflows. The resins - AVIPure - AAV9, AVIPure - AAV8, and AVIPure - AAV2 - were developed by Avitide, a Repligen company, and are specific to the major adeno-associated virus gene therapy vectors used today. Kevin Isett, President and CEO of Avitide said, "We are so pleased to introduce our AVIPure resins, which directly address the need for more advanced affinity solutions for gene therapy workflows. Caustic stability has been a challenge that these AVIPure resins now overcome, without sacrificing high dynamic binding capacity. We believe customers will benefit from superior process economics, including multi-cycle resin capabilities."

07:46 EST InMed Pharmaceuticals appoints VP of Sales, Marketing for BayMedica - InMed Pharmaceuticals announces the appointment of Gerard Griffin III as Vice President, VP, of Sales and Marketing at BayMedica, a wholly owned subsidiary of InMed. Most recently, Griffin was the Vice President of Sales and Business Development at Creo Ingredients.

07:45 EST AC Immune announces new ACI-35.030 Phase 1b/2a trial interim data - AC Immune announced new interim 10-week data from the high-dose cohort of a placebo-controlled Phase 1b/2a trial evaluating ACI-35.030, a first-in-class phosphorylated-Tau vaccine candidate in participants with early Alzheimer's disease, AD. The Company previously reported interim data from low-dose and mid-dose cohorts. ACI-35.030, based on AC Immune's SupraAntigen platform, is the first AD vaccine candidate designed to generate antibodies targeting pathological pTau in the brain. New interim data from the Phase 1b/2a trial show that the high-dose of ACI-35.030 led to the strong induction of antibodies selective for pTau and its aggregated form, enriched paired helical filaments. These data are consistent with those previously announced for the trial's mid-dose cohort that showed median anti-pTau antibody titers increasing from baseline by two orders of magnitude at week 2 after a first injection. Additional key findings from the high-dose interim analysis include: Results indicate that the induced immune response selectively targets pTau. In this interim data set to week 10, median levels of antibodies reactive with pathological Tau were boosted with both the first and second vaccine injections. Safety data provide further support for ACI-35.030's favorable safety and tolerability profile, as no clinically relevant safety concerns have been observed to date.

07:43 EST Intellia, ONK announce licensing, collaboration agreement - Intellia Therapeutics and ONK Therapeutics announced a licensing and collaboration agreement. NK cells are specialized, naturally occurring immune cells that play a critical role in immune activation against abnormal cells, including cancer cells. The agreement grants ONK a non-exclusive license to Intellia's proprietary ex vivo CRISPR/Cas9-based genome editing platform and its lipid nanoparticle-based delivery technologies to develop up to five allogeneic NK cell therapies. ONK will receive exclusive rights to certain Intellia guide RNAs resulting from the collaboration for use in engineering those NK cell products. ONK will be responsible for preclinical and clinical development for the engineered NK cell therapies covered under the agreement. Intellia will be eligible to receive up to $184M per product in development and commercial milestone payments, as well as up to mid-single digit royalties on potential future sales. In addition, the agreement grants Intellia options to co-develop and co-commercialize up to two products worldwide with rights to lead commercialization in the U.S. ONK retains lead commercialization rights ex-U.S. If Intellia chooses to exercise the co-development and co-commercialization option on an investigational product, in lieu of the potential royalties and milestones, Intellia will share 50 percent of any future profit and loss generated by the product.

07:39 EST Mustang Bio announces City of Hope Phase 1 trial on MB-105 presentation - Mustang Bio announced that City of Hope Phase 1 clinical trial data on MB-105, a prostate stem cell antigen chimeric antigen receptor T-cell therapy administered systemically to patients with PSCA-positive metastatic castration-resistant prostate cancer, has been selected for a poster presentation at the 2022 American Society of Clinical Oncology, ASCO, Genitourinary Cancers Symposium taking place February 17-19, 2022, both virtually and in San Francisco. The primary objectives of the Phase 1 clinical trial are to define the dose limiting toxicity, DLT, identify a recommended Phase 2 dose and describe preliminary bioactivity and efficacy. To date, 12 patients have been treated at City of Hope. Dosing began at 100 million cells without lymphodepletion chemotherapy, then lymphodepletion consisting of fludarabine and cyclophosphamide was added to 100M cells prior to dose escalation to a planned maximum of 600M cells. Three patients were treated at the 100M cell dose with no DLTs. In the 100M cells plus lymphodepletion dose level, two patients experienced DLT of grade 3 non-infective cystitis and fatigue. The protocol was amended to reduce the cyclophosphamide dose and to intensify the monitoring with early intervention for cystitis. Manuel Litchman, M.D., President and Chief Executive Officer of Mustang, said, "The Phase 1 data to be presented by Dr. Dorff on behalf of the City of Hope team demonstrate the potential of Mustang's MB-105 as a PSCA-targeted CAR T-cell therapy for prostate cancer. There is a potential to apply this therapy in other solid tumors that express PSCA. We remain encouraged by the ongoing progress of this trial as we develop our pipeline of cell therapy treatments for patients with cancers that are difficult to treat."

07:36 EST BrainStorm receives patent in Brazil covering methods to manufacture NurOwn - Brainstorm Cell Therapeutics announced that the Brazilian Patent Office has granted the patent application titled: "A method of generating cells which secrete Brain Derived Neurotrophic Factor, or BDNF, Glial Derived Neurotrophic Factor, or GDNF, Hepatocyte Growth Factor, or HGF, And Vascular Endothelial Growth Factor, or VEGF, wherein said cells do not Secrete Nerve Growth Factor, or NGF." The granted claims cover a method of manufacturing MSC-NTF cells, or NurOwn.

07:35 EST Wayfair announces Sean Halligan joins as chief global supply chain officer - Wayfair announced Sean Halligan has joined the company as chief global supply chain officer. Halligan will drive the strategic supply chain initiatives that enable Wayfair to deliver an exceptional shopping experience to its customers, from product discovery to final delivery including the ongoing expansion of Wayfair's fulfillment center and delivery network and the development of the company's global freight network.

07:34 EST Safehold executes private sale of Caret Units at a valuation of $1.75B - Safehold announced that it has closed on the sale of 108,571 Caret Units and received a binding commitment for the purchase of 28,571 Caret Units for $24M. Those 137,143 Caret Units equal 1.37% of the authorized Caret Units in Caret Ventures LLC, a subsidiary of Safehold, implying a total Caret Unit valuation of $1.75B. The Caret Units were purchased by a diversified group of leading FinTech, PropTech, institutional and high net worth investors, including Ribbit Capital, Fifth Wall, Zigg Capital, a leading sovereign wealth fund, Kevin Durant and Michael Rubin's family office. Safehold owns approximately 84% of the outstanding Caret Units following this sale. Safehold's management team owns approximately 15% of the Caret Units, which were earned through a shareholder approved long-term incentive plan after having reached certain stock price hurdles.

07:31 EST Alliance Data reports January net charge offs 4.6% vs. 4.5% last month - Reports January delinquency ratio 4.2% vs. 3.9% last month.

07:28 EST mCloud Technologies warrants to begin trading on Nasdaq on, about Feb. 15 - mCloud Technologies announced the warrants issued in connection with the company's underwritten public offering originally announced on November 24, 2021 have been approved for listing on Nasdaq. The Warrants are expected to commence trading on or about February 15 under the symbol "MCLDW." A total of 2,415,000 Warrants have been issued. Each Warrant enables the holder to acquire one common share of the company at a price of US$4.75 per share. The Warrants expire on November 29, 2026 and the CUSIP is 582270179.

07:24 EST Mount Logan announces director changes, executive compensation modification - Mount Logan Capital is pleased to announce the appointment of Robert Warshauer as a director of the Company and the chair of the Audit Committee. Mr. Warshauer is the Chief Executive Officer of BLST Holdings, LLC, the parent of Bluestem Brands, a billion-dollar consumer finance E-Commerce and catalog retailer. In connection with Mr. Warshauer's appointment, the Company also announces that Mr. Radford Small is retiring and is stepping down as a director. As a testament to management's commitment to and belief in Mount Logan's long-term value creation potential, CEO Ted Goldthorpe, and Co-Presidents, Matthias Ederer and Henry Wang, will receive no cash salary or bonuses of any kind for the 2022 fiscal year. Instead, their compensation will be 100% equity-based compensation granted pursuant to the Company's security-based compensation arrangements that vests over time for services rendered.

07:20 EST LGI Homes increase stock repurchase program by $200M - On February 11, 2022, the Company's Board of Directors increased the authorization for the repurchase of shares of the Company's common stock by $200.0 million. During the three months ended December 31, 2021, the Company repurchased 378,525 shares of its common stock for $56.1 million, bringing the remaining authorization under the Company's stock repurchase program to $106.6 million as of December 31, 2021. The Board's approval increases the aggregate amount available for stock repurchases to $306.6 million as of February 11, 2022. The timing, amount and other terms and conditions of any repurchases of shares of the Company's common stock under its stock repurchase program will be determined by management at its discretion based on a variety of factors, including the market price of the common stock, corporate considerations, general market and economic conditions and legal requirements. The Company's stock repurchase program may be modified, discontinued or suspended at any time.

07:18 EST Microbix Biosystems advances comissioning of sites two, three - Microbix Biosystems announces progress with expanding manufacturing capacity of its portfolio of Quality Assessment Products brand viral transport medium - via renovating and equipping its second and third manufacturing sites in Mississauga, ON. First, the final laboratory in Microbix's second production site is now validated to accommodate automated and larger-scale manufacturing of FLOQSwab-based and liquid-formatted QAPs, as well as ongoing DxTM production. Second, renovations have now commenced at Microbix's third site. This site is being re-engineered to accommodate larger-scale production of DxTM and build-out will be largely completed in the current fiscal quarter. Initially, Microbix's high-throughput, semi-automated production process will be installed in this site, to be quickly followed by more-automated production as soon as the necessary equipment is received and validated for use, expected in the quarter ending June 30, 2022. The goal of building-out and equipping these two sites is to expand production capacity for both QAPs and DxTM by five to tenfold current levels. Dr. Ken Hughes, Microbix's Chief Operating Officer, commented, "Our manufacturing spaces at 235 Watline have been designed to support our nearer-term scaling objectives for QAPs. We're entirely committed to enabling Microbix to make QAPs at the volumes needed to support global-scale test-makers. With respect to DxTM, we are commissioning custom-designed production and warehousing spaces at 275 Watline. Dedication of our third site for DxTM production is intended to provide Ontarians and Canadians a secure and strategic-scale supply of this vital patient-sample collection device."

07:16 EST AMC Entertainment to acquire, open Evanston 12 theater in Chicago - AMC announced it has reached a lease agreement with Chicago-based, GW Properties to acquire and open AMC Evanston 12, located in the Chicago area. The theatre is expected to open later this year. AMC remains in active discussions with other property owners regarding additional currently closed locations. Upon reopening, guests at AMC Evanston 12 can expect many of AMC's most popular amenities. Formally Evanston 18, six of the screens and restaurant space are being closed by GW Properties and renovated for non-theatre use.

07:14 EST Hudson Capital combines with Freight App, its adopts leadership team - Hudson Capital acquired 100% of Freight App as a wholly owned subsidiary on Monday, February 14, 2022. As part of the transaction, Hudson appointed Fr8App's leadership to replace Hudson's retiring board, CEO Warren Wang, and CFO Man Yun and adopted Fr8App's U.S. Headquarters in Houston, Texas. Effective February 15, 2022, Hudson Capital named Javier Selgas as CEO and Paul Freudenthaler as CFO. The newly appointed Board of Directors includes Selgas and independent directors Nicholas Adler, Marc Urbach, and William Samuels. "We believe, Fr8App, a U.S.-headquartered, North American company, is fast becoming a leader in transportation logistics technology with a focus on US-Mexico cross-border shipping. Fr8App grew revenue by 119% in 2020 and based on preliminary results, by 134% in 2021 over the prior year. Fr8App offerings provide compelling solutions to carrier and shipper partners and to logistics industry needs in general in a freight market that is second only in size to the US domestic fleet market," concluded Selgas.

07:13 EST Enthusiast Gaming's esports audience surpasses 145M social followers - Enthusiast Gaming (EGLX) announced the results of its latest custom study with Nielsen (NLSN) to measure the total social reach and Twitch viewership of the Company's Luminosity Gaming esports audience. The results of the latest custom Nielsen study for January 2022 show that Luminosity Gaming's total social following is now over 145M globally, having grown 13% since the last study in October 2021. In addition, the hours watched for Luminosity Gaming's esports team on Twitch surpassed 32M globally in January, an increase of 34% since the last study. "Luminosity is now head-and-shoulders above any other professional esports organization when it comes to time watched," commented Adrian Montgomery, CEO of Enthusiast Gaming. "This massive esports audience, combined with our top-ranked digital media property, makes Enthusiast Gaming the best partner for any major brand trying to connect with Gen Z and Millennials."

07:11 EST View smart windows selected for Trademark's new life science campus in Boston - View announced its smart windows will be installed at 100 Hood Park Drive, a seven-story spec office and laboratory building that will be a key component of Hood Park, a multi-building life science and technology hub developed by Trademark in Charlestown, Boston. View Smart Windows are expected to be installed in all office buildings in Hood Park as the extensive campus continues to be developed.

07:08 EST Accenture and League announce collaboration - Accenture and League, a health-focused platform-as-a-service company, announced collaboration. As part of the collaboration that combines Accenture's data analytics and systems integration capabilities with League's healthcare experience platform, the two companies will scale platform implementations and innovations to create personalized digital healthcare experiences. Accenture and League are currently working with Shoppers Drug Mart, Canada's leading retail pharmacy chain, to expand the capabilities of its PC Health platform, which provides people with a network of health care providers, health and wellness programs and rewards for completing health activities.

07:06 EST LianBio announces mavacamten granted BTD in China - LianBio announced that the Center for Drug Evaluation, CDE, of the National Medical Products Administration, NMPA, granted Breakthrough Therapy Designation, BTD, in China for mavacamten for the treatment of patients with obstructive hypertrophic cardiomyopathy, oHCM. Breakthrough Therapy Designation was supported by data from the global Phase 3 EXPLORER-HCM trial of mavacamten in oHCM patients with New York Heart Association class II-III symptoms. In the EXPLORER-HCM trial, mavacamten met all primary and secondary endpoints with statistical significance and demonstrated clinically meaningful improvement in functional status, symptoms, and quality of life. "In a global Phase 3 trial, mavacamten demonstrated the potential to change the course of disease and restore heart function in patients with oHCM," said Yizhe Wang, Ph.D., Chief Executive Officer of LianBio. "LianBio's Phase 3 trial of mavacamten in Chinese patients with symptomatic oHCM is ongoing, and we believe Breakthrough Therapy Designation will allow us to continue to accelerate the development of mavacamten in China. We look forward to working with CDE to deliver this important medicine to patients in need."

07:04 EST LGI Homes sees FY22 home closings 9,000-10,000 - Sees FY22 Active selling communities at the end of 2022 will be between 110 and 120; Average sales price per home closed will be between $315,000 and $330,000; Gross margin as a percentage of home sales revenues will be between 26.5% and 28.5%; Adjusted gross margin as a percentage of home sales revenues will be between 28.0% and 30.0% with capitalized interest accounting for substantially all the difference between gross margin and adjusted gross margin; SG&A as a percentage of home sales revenues will be between 9.0% and 10.0%; and Effective tax rate will be between 23.5% and 24.5%.

07:02 EST Marriott reports Q4 comparable systemwide constant dollar RevPAR up 124.5% - Fourth quarter 2021 comparable systemwide constant dollar RevPAR increased 124.5 percent worldwide, 143.6 percent in the U.S. & Canada, and 83.3 percent in international markets, compared to the 2020 fourth quarter. Fourth quarter 2021 comparable systemwide constant dollar RevPAR declined 19.0 percent worldwide, 15.3 percent in the U.S. & Canada, and 28.2 percent in international markets, compared to the 2019 fourth quarter.

06:57 EST Aecom appointed to Network Rail's Commercial Services Framework - AECOM announced it has been appointed to Network Rail's GBP45M Commercial Services Framework supporting the North West and Central, or NW&C, region of the U.K.'s rail network. The appointment continues AECOM's long-standing relationship with the region delivering technical, innovative and sustainable solutions to benefit Network Rail and all its passengers. The NW&C route runs from London Euston and Marylebone in the south through the Chiltern and West Midlands regions, the North West of England and Cumbria before joining with Scotland at Gretna. It includes key lines such as the West Coast Mainline, one of the busiest mixed-use passenger and freight railways in Europe, serving London, Birmingham, Manchester, Liverpool, Edinburgh and Glasgow.

06:53 EST ViewRay announces interim data from MIRAGE trial - ViewRay announced that interim data from the single center Phase III randomized MIRAGE trial, led by UCLA, comparing MRIdian MRI-guided vs. CT-guided SBRT for localized prostate cancer, will be featured at the 2022 American Society of Clinical Oncology, or ASCO, Genitourinary Cancers Symposium. Interim analysis of the primary endpoint signaled superiority of MRIdian MRI-guided SBRT with a significant reduction in acute grade greater than or equal to2 GU toxicity in men receiving MRI-guided SBRT over those receiving CT-guided SBRT. The interim analysis of data from 100 patients eligible for evaluation showed a statistically significant reduction in acute grade greater than or equal to two GU toxicity in men receiving MRI-guided SBRT and a significant reduction in acute grade greater than or equal to two gastrointestinal toxicity in men receiving MRI-guided SBRT. Acute grade greater than or equal to two GU toxicity can include adverse events range from frequent, urgent, or painful urination to pelvis pain, bladder spasms, or blood in the urine. Acute grade greater than or equal to two GI toxicity can include adverse events ranging from diarrhea, discharge, or rectal/abdominal pain to abdominal distention or obstruction. Patient-reported outcomes were measured using the International Prostate Symptom Score, or I-PSS, and Expanded Prostate cancer Index Composite, or EPIC-26. Patient reported urinary and bowel function metrics were better preserved at the one-month time point with MRI-guidance, though this difference dissipates at the 3-month time point, potentially due to management of side effects. Given the large primary endpoint signal seen, the study protocol was amended to reduce the projected sample size from 300 to 154, requiring half the number of patients while still maintaining 89% power to demonstrate superiority. Accrual of the MIRAGE trial was completed as of October 2021 and a final analysis for the primary endpoint is anticipated in early 2022.

06:50 EST Velodyne Lidar reaches 100 partner companies in its AwV program - Velodyne Lidar announced its Automated with Velodyne, or AwV, program now has 100 partner companies working to commercialize next-generation autonomous solutions using Velodyne's lidar sensors and software. The milestone demonstrates Velodyne's continued commitment in fostering the global marketplace and innovating lidar-based solutions that advance autonomy, safety and sustainability in a diverse range of industries.

06:36 EST Westlake Chemical changes name to Westlake Corporation - Westlake Chemical announced that it plans to officially change its name to Westlake Corporation effective on February 18. Westlake is now organized under one unified brand name with two financial reporting segments: Housing & Infrastructure Products and Performance & Essential Materials. The company's common stock will continue to trade under the ticker symbol "WLK" on the New York Stock Exchange.

06:35 EST ImmunoGen announces global licensing agreement with Eli Lilly - ImmunoGen (IMGN) announced a global, multi-year definitive licensing agreement whereby it granted Eli Lilly and Company (LLY) exclusive rights to research, develop, and commercialize ADCs directed to targets selected by Lilly based on ImmunoGen's novel camptothecin technology. ImmunoGen retains full rights to the camptothecin platform for all targets not covered by the Lilly license. As part of the agreement, Lilly will pay ImmunoGen an upfront payment of $13M, reflecting initial targets selected by Lilly. Lilly may select a pre-specified number of additional targets, with ImmunoGen eligible to receive an additional $32.5M in exercise fees if Lilly licenses the full number of targets. ImmunoGen is eligible to receive up to $1.7B in potential target program exercise fees and milestone payments based on the achievement of pre-specified development, regulatory, and commercial milestones. ImmunoGen is also eligible for tiered royalties as a percentage of worldwide commercial sales by Lilly. Lilly is responsible for all costs associated with research and development.

06:18 EST Billtrust acquires Order2Cash, terms not disclosed - Billtrust announced it has acquired Netherlands-based Order2Cash, a B2B order-to-cash platform provider. The acquisition follows the October 2021 purchase of iController, broadening the company's European footprint, global presence and ability to expand its innovative Business Payments Network. The Order2Cash team will continue to operate from Netherlands locations in Amsterdam and Joure, as well as offices in Krakow, Poland and New York City, USA

06:09 EST Otis Worldwide announces medium-term outlook at investor day - Sees organic sales up low to mid single digits in the medium term. Sees average adjusted operating profit margin expansion of 40 basis points annually. Sees adjusted EPS CAGR of 10%+ in the medium term. Sees free cash flow conversion between 100%-110% of GAAP net income in the medium term. Otis Worldwide is hosting its 2022 Investor Day virtually. During the event, Otis leadership will provide updates on the industry and the company's medium-term outlook, including its long-term growth strategy, margin expansion drivers and capital allocation plans.

06:08 EST Microsoft to reopen headquarters on February 28 - Microsoft is ready to reopen key offices after two years of pandemic-related closures and numerous delays, and now plans to enter the "final stage" of its Washington state return-to-work plan starting February 28 at which point facilities and services will be completely open to workers and visitors, the company said in a blog post. The company added: "When we originally shared our return to office approach with employees in the spring of 2020, our world looked much different. Throughout the past 18 months, we've seen exciting advances in science and medicine - from the development of vaccines to new strides in medical treatments. While the world has changed, our dedication to the safety and well-being of our employees has remained constant. As we navigate this new phase of work, we'll continue to take a data-driven approach to decision making that follows the guidance of public health authorities. We're maintaining a close watch on local health data in every area where Microsoft has a physical presence, and we'll adjust our course if necessary. We've learned a lot about working remotely in the last two years and we're fortunate to have the tools to continue doing so if needed." Reference Link

06:05 EST BTRS Holdings acquires Order2Cash, terms not disclosed - Billtrust announced it has acquired Netherlands-based Order2Cash, a B2B order-to-cash platform provider. The acquisition follows the October 2021 purchase of iController, broadening the company's European footprint, global presence and ability to expand its innovative Business Payments Network. The Order2Cash team will continue to operate from Netherlands locations in Amsterdam and Joure, as well as offices in Krakow, Poland and New York City, USA.

05:33 EST Ipsen announces two-year follow-up data from CheckMate -9ER trial - Ipsen announced two-year follow-up results from analyses of the Phase III CheckMate -9ER trial, which demonstrated sustained survival and response rate benefits, as well as health-related quality of life, or HRQoL, improvements, with the combination of Cabometyx and Opdivo versus sunitinib in the first-line treatment of advanced renal cell carcinoma, or aRCC. These updated results will be featured in two poster presentations at the American Society of Clinical Oncology Genitourinary Cancers Symposium, or ASCO GU, from February 17 to 19. With a median follow-up of 32.9 months, Cabometyx in combination with Opdivo continued to show superiority across efficacy endpoints of overall survival, or OS, progression-free survival, or PFS, objective response rate (ORR) and disease control rate, or DCR, including increased complete response, or CR, rates compared to sunitinib. For the secondary endpoint of median OS, the combination demonstrated a maintained clinically meaningful improvement, with a 30% reduction in the risk of death compared to sunitinib. PFS benefits, the primary endpoint of the study, were also maintained, with the combination continuing to double median PFS vs. sunitinib. Additionally, both superior ORR and DCR benefits were shown to be sustained with increased follow-up for the combination versus sunitinib; ORR 55.7% vs 28.4% and DCR 88.2% vs 69.3%. Moreover, among patients treated with the combination, 12.4% had a complete response vs 5.2% for sunitinib. In a further exploratory analysis of depth of response in target lesions by organ site, a higher percentage of patients experienced tumor shrinkage benefits with Cabometyx in combination with Opdivo vs. sunitinib across all organ sites assessed. The safety profile identified in the CheckMate -9ER trial was consistent with that previously observed for Cabometyx and Opdivo. 97.2% of patients treated with the combination experienced a treatment-related adverse event of any grade, compared to 93.1% of patients treated with sunitinib. Overall, 10.6% discontinued Opdivo only, 9.1% discontinued Cabometyx only, and 7.5% discontinued both Cabometyx and Opdivo. In a separate analysis, with 32.9 months median follow-up, patients continued to report clinically meaningful HRQoL benefits with Cabometyx in combination with Opdivo compared to sunitinib. These exploratory outcomes were measured using the Functional Assessment of Cancer Therapy Kidney Symptom Index-19 which assessed quality of life, or QoL, associated specifically to kidney cancer as well as EQ-5D-3L instruments which assessed QoL more generally. HRQoL scores from these instruments were found to be improved or maintained over time amongst patients treated with the combination, while reductions in scores were observed with sunitinib. Additionally, those who received the combination were 48% less likely to be notably bothered by treatment side effects than patients in the sunitinib arm. These updated data follow the publication of 23.5 month median follow-up HRQoL data in The Lancet Oncology, published on January 12.

05:17 EST Zealand Pharma completes patient enrollment in dasiglucagon trial - Zealand Pharma announced completion of patient enrollment in the second Phase 3-trial, 17103, of dasiglucagon for the treatment of Congenital hyperinsulinism, or CHI, in neonates up to 12 months old. This Phase 3 study is the last in the program which constitute the largest clinical development program ever conducted in CHI.

05:13 EST Boeing awarded three PBL contracts from ROK DAPA - Boeing has received three performance based logistics, or PBL, contracts from the Republic of Korea's Defense Acquisition Program Administration, or DAPA, to manage sustainment of Republic of Korea Air Force, or ROKAF, F-15K fighter jets and Airborne Early Warning & Control, or AEW&C, aircraft, and Republic of Korea Army, or ROKA, CH-47 Chinook helicopters. The five-year contracts will improve aircraft availability by using performance data to inform logistics and supply chain management activities.

05:07 EST Calliditas Therapeutics announces first patient randomized in TRANSFORM study - Calliditas Therapeutics announced that the first patient has been randomized in the company's pivotal phase 2b/3 TRANSFORM study in patients with primary biliary cholangitis, or PBC. The TRANSFORM trial is a 52-week, randomized, placebo-controlled, double-blind, adaptive Phase 2b/3 trial. It will initially investigate the effect of setanaxib 1200 mg/day and 1600 mg/day versus placebo on alkaline phosphatase, or ALP, reduction in patients with PBC and with elevated liver stiffness and intolerance or inadequate response to ursodeoxycholic acid, or UDCA. Key secondary endpoints include change from baseline in liver stiffness, assessed by transient elastography and change from baseline in fatigue. An interim analysis will be conducted once the 99th randomized patient has completed the Week 24 visit, which is expected H1 2023. The interim analysis outcome will determine which of the two doses will be selected for the Phase 3 portion of the trial. This global study will randomize a total of approximately 318 patients at up to 150 investigational centers, and expects to read out top line data in H2 2024/H1 2025.